<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1603233379
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Xolair
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OMALIZUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1796.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="VETTER PHARMA-FERTIGUNG, GMBH &amp; CO. KG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            VETTER PHARMA-FERTIGUNG, GMBH & CO. KG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Novartis Europharm Limited 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DX05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Xolair contains the active substance omalizumab. Omalizumab is a man-made protein that is similar to natural proteins produced by the body. It belongs to a class of medicines called monoclonal antibodies.</p><p>&nbsp;</p><p>Xolair is used for the treatment of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic asthma</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic rhinosinusitis (inflammation of the nose and sinuses) with nasal polyps</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic spontaneous urticaria (CSU)</p><p>&nbsp;</p><p><u>Allergic asthma</u></p><p>This medicine is used to prevent asthma from getting worse by controlling symptoms of severe allergic asthma in adults, adolescents and children (6&nbsp;years of age and older) who are already receiving asthma medicine, but whose asthma symptoms are not well controlled by medicines such as high-dose steroid inhalers and beta-agonist inhalers.</p><p>Chronic rhinosinusitis with nasal polyps</p><p>This medicine is used to treat chronic rhinosinusitis with nasal polyps in adults (18&nbsp;years of age and older) who are already receiving intranasal corticosteroids (corticosteroid nasal spray), but whose symptoms are not well controlled by these medicines. Nasal polyps are small growths on the lining of the nose. Xolair helps to reduce the size of the polyps and improves symptoms including nasal congestion, loss of sense of smell, mucus in the back of the throat and runny nose.</p><p>&nbsp;</p><p><u>Chronic spontaneous urticaria (CSU)</u></p><p>This medicine is used to treat chronic spontaneous urticaria in adults and adolescents (12&nbsp;years of age and older) who are already receiving antihistamines but whose CSU symptoms are not well controlled by these medicines.</p><p>&nbsp;</p><p>Xolair works by blocking a substance called immunoglobulin E (IgE), which is produced by the body. IgE contributes to a type of inflammation that plays a key role in causing allergic asthma, chronic rhinosinusitis with nasal polyps and CSU.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not use Xolair</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to omalizumab or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>If you think you may be allergic to any of the ingredients, tell your doctor as you should not use Xolair.</p><p>&nbsp;</p><p><strong>b. </strong><strong>Take special care with </strong><strong>Xolair</strong></p><p>&nbsp;Talk to your doctor before using Xolair:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have kidney or liver problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a disorder where your own immune system attacks parts of your own body (autoimmune disease).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are travelling to region where infections caused by parasites are common ‑ Xolair may weaken your resistance to such infections.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had a previous severe allergic reaction (anaphylaxis), for example resulting from a medicine, an insect bite or food.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had an allergic reaction to latex. The needle cap of the syringe may contain dry rubber (latex).</p><p>&nbsp;</p><p>Xolair does not treat acute asthma symptoms, such as a sudden asthma attack. Therefore Xolair should not be used to treat such symptoms.</p><p>&nbsp;</p><p>Xolair is not meant to prevent or treat other allergy-type conditions, such as sudden allergic reactions, hyperimmunoglobulin E syndrome (an inherited immune disorder), aspergillosis (a fungus-related lung disease), food allergy, eczema or hay fever because Xolair has not been studied in these conditions.</p><p>&nbsp;</p><p><strong>Look out for signs of allergic reactions and other serious side effects</strong></p><p>Xolair can potentially cause serious side effects. You must look out for signs of these conditions while you use Xolair. Seek medical help immediately if you notice any signs indicating a severe allergic reaction or other serious side effects. Such signs are listed under &ldquo;Serious side effects&rdquo; in section&nbsp;4.</p><p>&nbsp;</p><p>It is important that you receive training from your doctor in how to recognise early symptoms of severe allergic reactions, and how to manage these reactions if they occur, before you inject Xolair yourself or</p><p>before a non-healthcare professional gives you a Xolair injection (see section&nbsp;3, &ldquo;How to use Xolair&rdquo;). The majority of severe allergic reactions occur within the first 3&nbsp;doses of Xolair.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p><u>Allergic asthma</u></p><p>Xolair is not recommended for children under 6&nbsp;years of age. Its use in children under 6&nbsp;years of age has not been studied.</p><p>&nbsp;</p><p><u>Chronic rhinosinusitis with nasal polyps</u></p><p>Xolair is not recommended for children and adolescents under 18&nbsp;years of age. Its use in patients under 18&nbsp;years of age has not been studied.</p><p>&nbsp;</p><p><u>Chronic spontaneous urticaria (CSU)</u></p><p>Xolair is not recommended for children under 12&nbsp;years of age. Its use in children under 12 years of age has not been studied.</p><p>&nbsp;</p><p><strong>c. Using other medicines and Xolair</strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>This is especially important if you are taking:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat an infection caused by a parasite, as Xolair may reduce the effect of your medicines,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inhaled corticosteroids and other medicines for allergic asthma.</p><p>&nbsp;</p><p><strong>d. Pregnancy and breast-feeding</strong></p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. Your doctor will discuss with you the benefits and potential risks of using this medicine during pregnancy.</p><p>&nbsp;</p><p>If you become pregnant while being treated with Xolair, tell your doctor immediately.</p><p>&nbsp;</p><p>Xolair may pass into breast milk. If you are breast-feeding or plan to breast-feed, ask your doctor for advice before using this medicine.</p><p>&nbsp;</p><p><strong>e. Driving and using machines</strong></p><p>It is unlikely that Xolair will affect your ability to drive and use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor, nurse or pharmacist if you are not sure</p><p>&nbsp;</p><p><strong>How Xolair is used</strong></p><p>Xolair is used as an injection under your skin (known as a subcutaneous injection).</p><p>&nbsp;</p><p><u>Injecting Xolair</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You and your doctor will decide if you should inject Xolair yourself. The first 3&nbsp;doses are always given by or under the supervision of a healthcare professional (see section&nbsp;2).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is important to be properly trained on how to inject the medicine before injecting yourself.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A caregiver (for example a parent) may also give you your Xolair injection after he or she has received proper training.</p><p>&nbsp;</p><p>For detailed instructions on how to inject Xolair, see &ldquo;Instructions for use of Xolair pre-filled syringe&rdquo; at the end of this leaflet.</p><p>&nbsp;</p><p><u>Training to recognise serious allergic reactions</u></p><p>It is also important that you do not inject Xolair yourself until you have been trained by your doctor or nurse on:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; how to recognise the early signs and symptoms of serious allergic reactions</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; what to do if the symptoms occur.</p><p>For more information about the early signs and symptoms of serious allergic reactions, see section&nbsp;4.</p><p>&nbsp;</p><p><strong>How much to use</strong></p><p><u>Allergic asthma and chronic rhinosinusitis with nasal polyps</u></p><p>Your doctor will decide how much Xolair you need and how often you will need it. This depends on your body weight and the results of a blood test carried out before the start of the treatment to measure the amount of IgE in your blood.</p><p>&nbsp;</p><p>You will need 1 to 4&nbsp;injections at a time. You will need the injections either every two weeks, or every four weeks.</p><p>&nbsp;</p><p>Keep taking your current asthma and/or nasal polyps medicine during Xolair treatment. Do not stop taking any asthma and/or nasal polyps medicine without talking to your doctor.</p><p>&nbsp;</p><p>You may not see an immediate improvement after beginning Xolair treatment. In patients with nasal polyps effects have been seen 4&nbsp;weeks after the start of the treatment. In asthma patients it usually takes between 12 and 16&nbsp;weeks to have the full effect.</p><p>&nbsp;</p><p><u>Chronic spontaneous urticaria (CSU)</u></p><p>You will need two 150&nbsp;mg injections at a time every four weeks.</p><p>&nbsp;</p><p>Keep taking your current medicine for CSU during Xolair treatment. Do not stop taking any medicine without talking to your doctor.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p><u>Allergic asthma</u></p><p>Xolair can be used in children and adolescents aged 6&nbsp;years and older, who are already receiving asthma medicine, but whose asthma symptoms are not well controlled by medicines such as high dose steroid inhalers and beta-agonist inhalers. Your doctor will work out how much Xolair your child needs and how often it needs to be given. This will depend on your child&rsquo;s weight and the results of a blood test carried out before the start of the treatment to measure the amount of IgE in his/her blood.</p><p>&nbsp;</p><p>Children (6 to 11&nbsp;years of age) are not expected to self-administer Xolair. However, if considered appropriate by their doctor, a caregiver may give them their Xolair injection after proper training.</p><p>&nbsp;</p><p><u>Chronic rhinosinusitis with nasal polyps</u></p><p>Xolair should not be used in children and adolescents under 18&nbsp;years of age.</p><p><u>Chronic spontaneous urticaria (CSU)</u></p><p>Xolair can be used in adolescents aged 12&nbsp;years of age and older, who are already receiving antihistamines but whose CSU symptoms are not well controlled by these medicines. The dose for adolescents aged 12&nbsp;years and above is the same as for adults.</p><p>&nbsp;</p><p><strong>If a dose of Xolair is missed</strong></p><p>If you have missed an appointment, contact your doctor or hospital as soon as possible to re-schedule it.</p><p>&nbsp;</p><p>If you have forgotten to give yourself a dose of Xolair, inject the dose as soon as you remember. Then talk to your doctor to discuss when you should inject the next dose.</p><p>&nbsp;</p><p><strong>If you stop treatment with Xolair</strong></p><p>Do not stop treatment with Xolair unless your doctor tells you to. Interrupting or stopping the treatment with Xolair may cause your symptoms to come back.</p><p>&nbsp;</p><p>However, if you are being treated for CSU, your doctor may stop Xolair treatment from time to time so that your symptoms can be assessed. Follow your doctor&rsquo;s instructions.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The side effects caused by Xolair are usually mild to moderate but can occasionally be serious.</p><p>&nbsp;</p><p><u>Serious side effects</u>:</p><p>&nbsp;</p><p>Seek medical attention immediately if you notice any signs of the following side effects:</p><p>Rare (may affect up to 1 in 1,000&nbsp;people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic reactions (including anaphylaxis). Symptoms may include rash, itching or hives on the skin, swelling of the face, lips, tongue, larynx (voice box), windpipe or other parts of the body, fast heartbeat, dizziness and light-headedness, confusion, shortness of breath, wheezing or trouble breathing, blue skin or lips, collapsing and losing consciousness. If you have a history of severe allergic reactions (anaphylaxis) unrelated to Xolair you may be more at risk of developing a severe allergic reaction following use of Xolair.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Systemic lupus erythematosus (SLE). Symptoms may include muscle pain, joint pain and swelling, rash, fever, weight loss, and fatigue.</p><p>&nbsp;</p><p>Not known (frequency cannot be estimated from the available data)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Churg-Strauss syndrome or hypereosinophilic syndrome. Symptoms may include one or more of the following: swelling, pain or rash around blood or lymph vessels, high level of a specific type of white blood cells (marked eosinophilia), worsening problems with breathing, nasal congestion, heart problems<strong><em>, </em></strong>pain, numbness, tingling in the arms and legs.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood platelet count with symptoms such as bleeding or bruising more easily than normal.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serum sickness. Symptoms may include one or more of the following: joint pain with or without swelling or stiffness, rash, fever, swollen lymph nodes, muscle pain.</p><p><u>Other side effects include:</u></p><p>Very common (may affect more than 1 in 10&nbsp;people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (in children)</p><p>&nbsp;</p><p>Common (may affect up to 1 in 10&nbsp;people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reactions at the injection site including pain, swelling, itching and redness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the upper part of the tummy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache (very common in children)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory tract infection, such as inflammation of the pharynx and common cold</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of pressure or pain in the cheeks and forehead (sinusitis, sinus headache)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in joints (arthralgia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy</p><p>&nbsp;</p><p>Uncommon (may affect up to 1 in 100&nbsp;people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sleepy or tired</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tingling or numbness of the hands or feet</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting, low blood pressure while sitting or standing (postural hypotension), flushing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore throat, coughing, acute breathing problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea), diarrhoea, indigestion</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching, hives, rash, increased sensitivity of the skin to sun</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight increase</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu-like symptoms</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling arms</p><p>&nbsp;</p><p>Rare (may affect up to 1 in 1,000&nbsp;people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; parasitic infection</p><p>&nbsp;</p><p>Not known (frequency cannot be estimated from the available data)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain and joint swelling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.&nbsp;The carton containing the pre-filled syringe can be stored for a total time of 48 hours at room temperature (25&deg;C) before use.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from light.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use any pack that is damaged or shows signs of tampering.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is omalizumab. One syringe of 1&nbsp;ml solution contains 150&nbsp;mg omalizumab.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are L-arginine hydrochloride, L-histidine hydrochloride, L-histidine, Polysorbate 20 and water for injections.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The needle cap of the syringe may contain dry rubber (latex).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Xolair solution for injection is supplied as a clear to slightly opalescent, colourless to pale brownish yellow solution in a pre-filled syringe.

Xolair 150 mg solution for injection in pre-filled syringe with 26-gauge staked needle and purple syringe guard is available in packs containing 1 pre-filled syringe and in multipacks containing 4 (4 x 1), 6 (6 x 1) or 10 (10 x 1) pre-filled syringes.

Not all pack sizes may be marketed in your country.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                02/2023
e. To report any side effect(s):
•	Saudi Arabia

Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):
o SFDA call center: 19999
o E-mail: npc.drug@sfda.gov.sa
o Website: https://ade.sfda.gov.sa 

Patient Safety Department Novartis Consulting AG - Saudi Arabia:
o Toll Free Number: 8001240078
o Phone: +966112658100 
o Fax: +966112658107
o Email: adverse.events@novartis.com  

•    Other GCC States:
-  Please contact the relevant competent authority.

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي عقار زولير على المادة الفعّالة أوماليزوماب. أوماليزوماب عبارة عن بروتين من صنع البشر وهو مماثل للبروتينات الطبيعية التي ينتجها الجسم. فهو ينتمي إلى فئة من الأدوية تُسمى الأجسام المضادة أحادية النسيلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم عقار زولير لعلاج الحالات الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو التحسسي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأنف والجيوب المزمن المصحوب بسَلائِل أَنْفِيَّة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأرتكاريا التلقائية المزمنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الربو التَّحسسي</u></p><p dir="RTL">يُستخدم هذا الدَّواء لمنع تفاقم مرض الربو عن طريق التَّحكم في أعراض الربو التَّحسسي الشَّديد لدى البالغين والمراهقين والأطفال (بعمر 6 أعوام فأكبر) ممن يتلقون بالفعل دواء للربو، لكن أعراض الربو لديهم لا يتم التَّحكم فيها بشكل جيد عن طريق استخدام أدوية مثل أجهزة الاستنشاق التي تحتوي على الستيرويدات وناهضات بيتا بجرعة مرتفعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">التهاب الأنف والجيوب المزمن المصحوب بسَلائِل أَنْفِيَّة</p><p dir="RTL">يُستخدم هذا الدَّواء لعلاج التهاب الأنف والجيوب المزمن المصحوب بسَلائِل أَنْفِيَّة لدى البالغين (بعمر 18 عامًا فأكبر) ممن يتلقون بالفعل الكورتيكوستيرويدات داخل الأنف (بخاخ للأنف يحتوي على كورتيكوستيرويد) ولكن لا يتم التَّحكم في الأعراض لديهم بشكل جيد عن طريق استخدام هذه الأدوية. السَّلائِلُ الأَنْفِيَّة هي عبارة عن زوائد صغيرة ببطانة الأنف. يساعد عقار زولير على خفض حجم السلائل كما يحسن الأعراض، بما في ذلك احتقان الأنف وفقدان حاسة الشم ووجود مخاط بالجزء الخلفي من الحلق وسيلان الأنف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأرتكاريا التلقائية المزمنة</u></p><p dir="RTL">يُستخدم هذا الدَّواء لعلاج الأرتكاريا التلقائية المزمنة لدى البالغين والمراهقين (بعمر 12 عامًا فأكبر) ممن يتلقون بالفعل مضادات الهيستامين ولكن أعراض الأرتكاريا التلقائية المزمنة التي يعانون منها لا يتم التَّحكم فيها بشكل جيد عن طريق استخدام هذه الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعمل عقار زولير عن طريق إعاقة مادة تُسمى الجلوبيولين المناعي &quot;E&quot;، والتي ينتجها الجسم. يساهم الجلوبيولين المناعي &quot;E&quot; في حدوث نوع من الالتهاب الذي يلعب دورًا رئيسيًّا في التَّسبب بالإصابة بالربو التحسسي، والتهاب الأنف والجيوب المزمن المصحوب بسَلائِل أَنْفِيَّة والأرتكاريا التلقائية المزمنة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ</strong><strong>. </strong><strong>موانع استعمال عقار زولير</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه أوماليزوماب أو تجاه أي مكون من المكونات الأخرى الموجودة بهذا الدَّواء (المدرجة في القسم: 6).</p><p dir="RTL">إذا كنت تعتقد أنه قد تكون لديك حساسية تجاه أيٍّ من المكونات، فأخبر طبيبك؛ حيث يجب عليك عدم استخدام عقار زولير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب</strong><strong>.</strong> <strong>الاحتياطات عند استعمال عقار زولير</strong></p><p dir="RTL">&nbsp;تحدَّث إلى طبيبك قبل استخدام عقار زولير في الحالات الآتية:</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كان لديك مشاكل بالكلى أو الكبد.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت تُعاني من أحد الاضطرابات؛ حيث يهاجم الجهاز المناعي لديك أجزاء من جسمك (مرض مناعي ذاتي).</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت مسافرًا إلى منطقة تنتشر فيها العدوى النَّاجمة عن الطفيليات -فقد يُضعِف عقار زولير مقاومتك تجاه هذه العدوى.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كُنت قد أصِبت سابقًا بتفاعل حساسية شديد (تأق)، على سبيل المثال، ناجم عن استخدام أحد الأدوية، أو لدغة حشرة أو تناوُل الطعام.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت قد أُصِبت من قبل بأحد تفاعلات الحساسية تجاه مادة اللاتكس. قد يحتوي غطاء إبرة السرنجة على مطاط جاف (لاتكس).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُعالج عقار زولير أعراض مرض الربو الحاد، مثل نوبة الربو المفاجئة. لذلك، يجب عدم استخدام عقار زولير لعلاج هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ليس المقصود من استخدام عقار زولير الوقاية من الحالات الأخرى من النوع التحسسي أو علاجها، مثل تفاعلات الحساسية المفاجئة، متلازمة فرط الجلوبيولين المناعي &quot;E&quot; (وهو اضطراب مناعي وراثي)، داء الرَّشَّاشِيَّات (وهو مرض رئوي مرتبط بالفطريات)، حساسية الطعام، الأكزيما أو حُمَّى القش؛ نظرًا لعدم دراسة استخدام عقار زولير في هذه الحالات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يُرجى الانتباه إلى علامات تفاعلات الحساسية وغيرها من الآثار الجانبية الخطيرة</strong></p><p dir="RTL">من الممكن أن يسبب عقار زولير آثارًا جانبية خطيرة. يجب عليك الانتباه إلى علامات هذه الحالات أثناء استخدام عقار زولير. اطلب المساعدة الطبية فورًا إذا لاحظت أية علامات تدل على حدوث أحد تفاعلات الحساسية الشديدة أو أية آثار جانبية خطيرة أخرى. هذه العلامات مُدرجة تحت &quot;الآثار الجانبية الخطيرة&quot; في القسم: 4.</p><p dir="RTL">&nbsp;</p><p>من المهم أن تتلقى تدريبًا من طبيبك على كيفية التَّعرف على الأعراض المبكرة لتفاعلات الحساسية الشديدة، وكيفية علاج</p><p dir="RTL">هذه التفاعلات إذا حدثت، قبل أن تقوم بحقن عقار زولير بنفسك أو قبل أن يعطيك أخصائي بخلاف أخصائيي الرعاية الصحية حقنة عقار زولير (انظر القسم: 3، &quot;كيفية استخدام عقار زولير&quot;). تحدث أغلب تفاعلات الحساسية الشديدة خلال تلقي أول 3 جرعات من عقار زولير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL"><u>الربو التَّحسسي</u></p><p dir="RTL">لا يوصى باستخدام عقار زولير للأطفال ممن تقل أعمارهم عن 6 أعوام. لم تتم دراسة استخدام العقار في الأطفال ممن تقل أعمارهم عن 6 أعوام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التهاب الأنف والجيوب المزمن المصحوب بسَلائِل أَنْفِيَّة</u></p><p dir="RTL">لا يوصى باستخدام عقار زولير للأطفال والمراهقين ممن تقل أعمارهم عن 18 عامًا. لم تتم دراسة استخدام العقار في المرضى ممن تقل أعمارهم عن 18 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأرتكاريا التلقائية المزمنة</u></p><p dir="RTL">لا يوصى باستخدام عقار زولير للأطفال ممن تقل أعمارهم عن 12 عامًا لم تتم دراسة استخدام العقار في الأطفال ممن تقل أعمارهم عن 12 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج</strong><strong>. </strong><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">يُرجى إخبار طبيبك أو الصيدلي أو الممرض(ة) الخاص(ة) بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذا الأمر مهم بشكل خاص إذا كنت تتناول الآتي:</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الأدوية التي تستخدم لعلاج العدوى النَّاجمة عن أحد الطفيليات؛ حيث إنَّ عقار زولير قد يخفض من تأثير الأدوية الخاصة بك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكورتيكوستيرويدات المستنشقة وغيرها من أدوية علاج الربو التحسسي.</p><p dir="RTL"><strong>د</strong><strong>. </strong><strong>الحمل والرضاعة </strong></p><p dir="RTL">إذا كنتِ حاملًا، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ قبل استخدام هذا الدَّواء. سيناقش معكِ طبيبكِ الفوائد والمخاطر المُحتملة لاستخدام هذا الدواء أثناء فترة الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبحتِ حاملًا أثناء العلاج بعقار زولير، فيجب عليكِ إخبار طبيبكِ فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يمر عقار زولير في لبن الأم. إذا كنتِ مرضعًا أو تخططين لممارسة الرضاعة الطبيعية، فاستشيري طبيبكِ قبل استخدام هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ه</strong><strong>. </strong><strong>تأثير عقار زولير على</strong><strong> </strong><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المرجح أن يُؤثر عقار زولير في قدرتك على القيادة واستخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. راجع طبيبك أو الممرض(ة) أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية استخدام عقار زولير</strong></p><p dir="RTL">يُستخدم عقار زولير في هيئة حقن تحت الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>حَقْن عقار زولير</u></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ستقرر أنت وطبيبك ما إذا كان يجب عليك حقن عقار زولير بنفسك أم لا. دائمًا ما يتم إعطاء أول 3 جرعات عن طريق أو تحت إشراف أحد أخصائيي الرعاية الصحية (انظر القسم: 2).</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>من المهم أن يتم تدريبك بشكل صحيح على كيفية حقن الدَّواء قبل حقن نفسك.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>قد يعطيك/ تعطيك أيضًا مقدم(ة) الرعاية (على سبيل المثال: أحد الوالدين) حقنة عقار زولير الخاصَّة بك بعد تلقيه/ تلقيها التَّدريب المناسب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للحصول على إرشادات مفصلة حول كيفية حقن عقار زولير، انظر: &quot;تعليمات استخدام سرنجة عقار زولير المعبأة مسبقًا&quot; في نهاية هذه النَّشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التَّدريب على التَّعرف على تفاعلات الحساسية الخطيرة</u></p><p dir="RTL">من المهم أيضًا عدم حقن عقار زولير بنفسك حتى يتم تدريبك من قبل طبيبك أو الممرض(ة) الخاص(ة) بك على الآتي:</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>كيفية التَّعرف على العلامات والأعراض المبكرة لتفاعلات الحساسية الخطيرة.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ما يجب فعله إذا حدثت الأعراض.</p><p dir="RTL">للحصول على مزيد من المعلومات حول العلامات والأعراض المبكرة لتفاعلات الحساسية الخطيرة، انظر القسم: 4.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما الكمية التي يجب أن تستخدمها؟</strong></p><p dir="RTL"><u>الربو التحسسي والتهاب الأنف والجيوب المزمن المصحوب بسَلائِل أَنْفِيَّة</u></p><p dir="RTL">سيقرر طبيبك كمية عقار زولير التي تحتاجها وعدد المرات التي ستحتاج إليها. يعتمد ذلك على وزن جسمك ونتائج اختبار الدَّم الذي تم إجراؤه قبل بدء العلاج لقياس كمية الجلوبيولين المناعي &quot;E&quot; لديك بالدَّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ستكون بحاجة إلى تلقي حقنة واحدة إلى 4 حُقن في المرة الواحدة. ستحتاج إلى تلقي الحُقن إما كل أسبوعين، أو كل أربعة أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استمر في تلقي دواء الربو و/أو السَّلائِل الأَنْفِيَّة الحالي الخاص بك أثناء العلاج بعقار زولير. يجب ألا تتوقف عن تلقي أي دواء للربو و/أو السَّلائِل الأَنْفِيَّة دون التَّحدث إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تلاحظ حدوث أي تحسن فوري بعد بدء العلاج بعقار زولير. لُوحظ لدى المرضى الذين يعانون من سَلائِل أَنْفِيَّة حدوث التأثيرات بعد 4 أسابيع من بدء العلاج. في المرضى الذين يعانون من الربو عادة ما يستغرق ذلك ما بين 12 و 16 أسبوعًا؛ للحصول على التَّأثير الكامل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأرتكاريا التلقائية المزمنة</u></p><p dir="RTL">ستكون بحاجة إلى تلقي حقنتين بمقدار 150 مجم في المرة الواحدة كل أربعة أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استمر في تلقي دواء الأرتكاريا التلقائية المزمنة الحالي الخاص بك أثناء العلاج بعقار زولير. يجب ألا تتوقف عن تلقي أي دواء دون التَّحدث إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام في الأطفال والمراهقين</strong></p><p dir="RTL"><u>الربو التَّحسسي</u></p><p dir="RTL">من الممكن استخدام عقار زولير في الأطفال والمراهقين بعمر 6 أعوام فأكبر، ممن يتلقون بالفعل دواء للربو، لكن أعراض الربو لديهم لا يتم التَّحكم فيها بشكل جيد عن طريق استخدام أدوية مثل أجهزة الاستنشاق التي تحتوي على الستيرويدات وناهضات بيتا بجرعة مرتفعة. سيحدد طبيبك كمية عقار زولير التي يحتاجها طفلك وعدد المرات اللازمة لإعطائها. سيعتمد ذلك على وزن طفلك/ طفلتك ونتائج اختبار الدَّم الذي تم إجراؤه قبل بدء العلاج لقياس كمية الجلوبيولين المناعي &quot;E&quot; لديه/ لديها بالدّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المتوقع إعطاء الأطفال (من عمر 6 إلى 11 عامًا) عقار زولير لأنفسهم، مع ذلك، إذا اعتبر طبيبهم أنَّ ذلك مناسبًا، فقد يعطيهم مقدم الرعاية حقنة عقار زولير الخاصَّة بهم بعد تلقي التَّدريب المناسب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التهاب الأنف والجيوب المزمن المصحوب بسَلائِل أَنْفِيَّة</u></p><p dir="RTL">لا يجب استخدام عقار زولير في الأطفال والمراهقين ممن تقل أعمارهم عن 18 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأرتكاريا التلقائية المزمنة</u></p><p dir="RTL">من الممكن استخدام عقار زولير في المراهقين بعمر 12 عامًا فأكبر، ممن يتلقون بالفعل مضادات الهيستامين ولكن</p><p dir="RTL">أعراض الأرتكاريا التلقائية المزمنة التي يعانون منها لا يتم التَّحكم فيها بشكل جيد عن طريق استخدام هذه الأدوية. تكون الجرعة بالنسبة للمراهقين بعمر 12 عامًا فأكبر هي نفسها التي تُستخدم بالنسبة للبالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تم إغفال إحدى جرعات عقار زولير</strong></p><p dir="RTL">إذا أغفلت موعدًا، فاتصل بطبيبك أو المستشفى في أقرب وقت ممكن لإعادة تحديد موعد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت قد أغفلت إعطاء نفسك إحدى جرعات عقار زولير، فاحقن الجرعة بمجرد أن تتذكر. ثم تحدَّث إلى طبيبك لمناقشة متى يجب عليك حقن الجرعة التَّالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أوقفت العلاج بعقار زولير</strong></p><p dir="RTL">لا توقف العلاج بعقار زولير ما لم يخبرك طبيبك بذلك. قد يسبب قطع أو إيقاف العلاج بعقار زولير معاودة الأعراض التي تعاني منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مع ذلك، إذا كنت تُعالج من الأرتكاريا التلقائية المزمنة، فقد يوقف طبيبك العلاج باستخدام عقار زولير من وقت لآخر حتى يمكن تقييم الأعراض التي تعاني منها. يُرجى اتباع تعليمات طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي أو الممرض(ة) الخاص(ة) بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع. عادةً ما تكون الآثار الجانبية النَّاجمة عن استخدام عقار زولير خفيفة إلى متوسطة، ولكنها قد تكون خطيرة أحيانًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الآثار الجانبية الخطيرة</u><u>:</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">اطلب العناية الطبية فورًا إذا لاحظت أي علامات للآثار الجانبية الآتية:</p><p dir="RTL">نادرة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية شديدة (بما في ذلك التَّأق). قد تشمل الأعراض طفحًا جلديًّا أو حكة أو شرى (أرتكاريا) على الجلد، تورمًا بالوجه، الشفتين، اللسان، الحنجرة، الرُّغامَى (القصبة الهوائية) أو أجزاء أخرى من الجسم، تسارع ضربات القلب، دوخة وشعورًا بخفة الرَّأس، ارتباكًا، ضيق التنفس، أزيزًا بالصدر أو صعوبة في التنفس، تحول لون الجلد أو الشفتين إلى اللون الأزرق، هبوطًا وفقدان الوعي. إذا كان لديك تاريخ مرضي من الإصابة بتفاعلات الحساسية الشديدة (التَّأق) غير المرتبطة بعقار زولير، فقد تكون أكثر عرضة لخطر الإصابة بأحد تفاعلات الحساسية الشديدة بعد استخدام عقار زولير.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الذِّئْبَة الحُمَامِيَّة الجَهازِيَّة. قد تتضمن الأعراض ألمًا في العضلات وألمًا وتورمًا بالمفاصل وطفحًا جلديًّا وحمى وفقدان الوزن وإرهاقًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير معروفة (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>متلازمة شيرج -ستراوس أو متلازمة فرط اليوزينيات. قد تتضمن الأعراض واحدًا أو أكثر مما يلي: تورمًا، ألمًا أو طفحًا جلديًّا حول الأوعية الدَّموية أو الليمفاوية، ارتفاع مستوى نوع معين من خلايا الدَّم البيضاء (كثرة ملحوظة بعدد خلايا اليُوزينِيَّات)، تفاقم مشاكل التَّنفس، احتقان الأنف، مشاكل القلب، ألمًا، تنميلًا، وخزًا بالذراعين والساقين.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>انخفاض تعداد الصفائح الدَّموية مع أعراض مثل النزيف أو التَّكدم بسهولة بشكل أكثر من المعتاد.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>داء المصل. قد تشمل الأعراض واحدًا أو أكثر مما يلي: ألمًا بالمفاصل مع أو بدون تورم أو تيبُّس، طفحًا جلديًّا، حمى، تورم العقد الليمفاوية، ألمًا في العضلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تتضمن الآثار الجانبية الأخرى ما يلي</u><u>:</u></p><p dir="RTL">شائعة جدًّا (قد تُؤثر على أكثر من شخص واحد من بين كل 10&nbsp;أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى (في الأطفال).</p><p dir="RTL">شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات بموضع الحقن، بما في ذلك ألم وتورم وحكة واحمرار.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالجزء العلوي من البطن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع (شائع جدًّا في الأطفال).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بالجهاز التَّنفسي العلوي، مثل التهاب البلعوم والإصابة بنزلة برد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بضغط أو ألم في الخدين والجبهة (الْتِهاب الجُيوب الأنفية وصداع الجيوب الأنفية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمفاصل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوخة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بنعاس أو تعب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وخز أو تنميل باليدين أو القدمين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء، انخفاض ضغط الدَّم أثناء الجلوس أو الوقوف (انخفاض ضغط الدم الوضعي)، احمرار الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق، سعال، مشاكل حادة بالتَّنفس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء (الغثيان)، إسهال وعسر الهضم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة، شرى (أرتكاريا)، طفح جلدي، زيادة حساسية الجلد تجاه الشمس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض شبيهة بأعراض الأنفلونزا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم بالذراعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى طفيلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير معروفة (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالعضلات وتورم المفاصل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدَّواء بعد تاريخ انتهاء الصّلاحية المدون على الملصق. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.&nbsp;يمكن تخزين العلبة التي تحتوي على السرنجة المعبأة مسبقًا لمدة إجمالية قدرها 48 ساعة في درجة حرارة الغرفة (25 درجة مئوية) قبل الاستخدام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُخزن داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ في الثلاجة (عند 2&mdash;8 درجات مئوية). لا تعرضه للتَّجميد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم أي عبوة تالفة أو تظهر عليها علامات العبث</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي أوماليزوماب. تحتوي السرنجة الواحدة التي بها 1 مللي لتر من المحلول على 150 مجم من أوماليزوماب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: هيدروكلوريد إل-أرجينين، هيدروكلوريد إل-هيستيدين، إل-هيستيدين، بوليسوربات 20 وماء للحَقن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يحتوي غطاء إبرة السرنجة على مطاط جاف (لاتكس).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوافر عقار زولير محلول للحقن في هيئة محلول صافٍ إلى ضبابي بعض الشيء وعديم اللون إلى أصفر شاحب يميل إلى البني في سرنجة معبأة مسبقًا.</p><p dir="RTL">يتوفر عقار زولير 150 مجم محلول للحقن في سرنجة معبأة مسبقًا بإبرة مثبتة مقاس 26، وواقي حقنة أرجواني في عبوات تحتوي على سرنجة واحدة معبأة مسبقًا، وفي عبوات متعددة تحتوي على 4 (4 &times; 1)، 6 (6 &times; 1) أو 10 (10 &times; 1) سرنجات معبأة مسبقًا.يتوفر عقار زولير 150 مجم محلول للحقن في سرنجة معبأة مسبقًا بإبرة مثبتة مقاس 26، وواقي حقنة أرجواني في عبوات تحتوي على سرنجة واحدة معبأة مسبقًا، وفي عبوات متعددة تحتوي على 4 (4 &times; 1)، 6 (6 &times; 1) أو 10 (10 &times; 1) سرنجات معبأة مسبقًا.</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات ببلدك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            02/2023
هـ.  للإبلاغ عن الأعراض الجانبية : 
•	المملكة العربية السعودية

   - المركز الوطني للتيقظ والسلامة الدوائية (NPC)
•	مركز اتصال الهيئة السعودية للغذاء والدواء: 19999
•	البريد الالكتروني: npc.drug@sfda.gov.sa
•	الموقع الالكتروني: https://ade.sfda.gov.sa

-	شركة نوفارتس - السعودية - قسم سلامة المرضى:
•	الهاتف المجاني: 8001240078
•	الهاتف:  +966112658100
•	الفاكس: +966112658107
•	البريد الالكتروني: adverse.events@novartis.com

•	دول مجلس التَّعاون الخليجي الأخرى: 
- يُرجى الاتصال بسلطات الاختصاص المعنية

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xolair 150 mg solution for injection in pre-filled syringe
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each pre-filled syringe of 1 ml solution contains 150 mg of omalizumab*.
*Omalizumab is a humanised monoclonal antibody manufactured by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell line.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection in pre-filled syringe (injection).
Clear to slightly opalescent, colourless to pale brownish-yellow solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Allergic asthma</u></p><p>Xolair is indicated in adults, adolescents and children (6 to &lt;12&nbsp;years of age).</p><p>Xolair treatment should only be considered for patients with convincing IgE (immunoglobulin E) mediated asthma (see section&nbsp;4.2).</p><p><em><u>Adults and adolescents (12&nbsp;years of age and older)</u></em></p><p>Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1 &lt;80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.</p><p><em><u>Children (6 to &lt;12&nbsp;years of age)</u></em></p><p>Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.</p><p><u>Chronic rhinosinusitis with nasal polyps (CRSwNP)</u></p><p>Xolair is indicated as an add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18&nbsp;years and above) with severe CRSwNP for whom therapy with INC does not provide adequate disease control.</p><p><u>Chronic spontaneous urticaria (CSU)</u></p><p>Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12&nbsp;years and above) patients with inadequate response to H1 antihistamine treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated by physicians experienced in the diagnosis and treatment of severe persistent asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) or chronic spontaneous urticaria.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p><em><u>Allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)</u></em></p><p>Dosing for allergic asthma and CRSwNP follows the same dosing principles. The appropriate dose and frequency of Xolair for these conditions is determined by baseline IgE (IU/ml), measured before the start of treatment, and body weight (kg). Prior to administration of the initial dose, patients should have their IgE level determined by any commercial serum total IgE assay for their dose assignment. Based on these measurements, 75 to 600&nbsp;mg of Xolair in 1 to 4&nbsp;injections may be needed for each administration.</p><p>&nbsp;</p><p>Allergic asthma patients with baseline IgE lower than 76&nbsp;IU/ml were less likely to experience benefit (see section&nbsp;5.1). Prescribing physicians should ensure that adult and adolescent patients with IgE below 76&nbsp;IU/ml and children (6 to &lt;&nbsp;12&nbsp;years of age) with IgE below 200&nbsp;IU/ml have unequivocal <em>in vitro</em> reactivity (RAST) to a perennial allergen before starting therapy.</p><p>&nbsp;</p><p>See Table&nbsp;1 for a conversion chart and Tables&nbsp;2 and 3 for the dose determination charts.</p><p>&nbsp;</p><p>Patients whose baseline IgE levels or body weight in kilograms are outside the limits of the dose table should not be given Xolair.</p><p>&nbsp;</p><p>The maximum recommended dose is 600&nbsp;mg omalizumab every two weeks.</p><p>&nbsp;</p><p><strong>Table&nbsp;1</strong><strong> Conversion from dose to number of syringes, number of injections and total injection volume for each administration</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Dose (mg)</p></td><td colspan="2" style="vertical-align:top"><p>Number of syringes</p></td><td style="vertical-align:top"><p>Number of injections</p></td><td style="vertical-align:top"><p>Total injection volume (ml)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>75&nbsp;mg<sup> </sup></p></td><td style="vertical-align:top"><p>150&nbsp;mg<sup> </sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1.5</p></td></tr><tr><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>2.5</p></td></tr><tr><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>3.0</p></td></tr><tr><td style="vertical-align:top"><p>525</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>3.5</p></td></tr><tr><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4.0</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table&nbsp;2 </strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADMINISTRATION EVERY 4&nbsp;WEEKS. Xolair doses (milligrams per dose) administered by subcutaneous injection every 4&nbsp;weeks</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="10" style="vertical-align:bottom"><p><strong>Body weight (kg)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Baseline IgE (IU/ml)</strong></p></td><td style="vertical-align:bottom"><p>&sup3;20‑25*</p></td><td style="vertical-align:bottom"><p>&gt;25‑<br />30*</p></td><td style="vertical-align:bottom"><p>&gt;30‑<br />40</p></td><td style="vertical-align:bottom"><p>&gt;40‑<br />50</p></td><td style="vertical-align:bottom"><p>&gt;50‑<br />60</p></td><td style="vertical-align:bottom"><p>&gt;60‑<br />70</p></td><td style="vertical-align:bottom"><p>&gt;70‑<br />80</p></td><td style="vertical-align:bottom"><p>&gt;80‑<br />90</p></td><td style="vertical-align:bottom"><p>&gt;90‑<br />125</p></td><td style="vertical-align:bottom"><p>&gt;125‑<br />150</p></td></tr><tr><td style="vertical-align:top"><p>&sup3;30‑100</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>300</p></td></tr><tr><td style="vertical-align:top"><p>&gt;100‑200</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>600</p></td></tr><tr><td style="vertical-align:top"><p>&gt;200‑300</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;300‑400</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;400‑500</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;500‑600</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;600‑700</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;700‑800</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;800‑900</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="5" rowspan="2" style="vertical-align:top"><p>ADMINISTRATION EVERY 2&nbsp;WEEKS</p><p>SEE TABLE&nbsp;3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;900-1000</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;1000-1100</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>*Body weights below 30&nbsp;kg were not studied in the pivotal trials for CRSwNP.</p><p>&nbsp;</p><p><strong>Table&nbsp;3 </strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ADMINSTRATION EVERY 2&nbsp;WEEKS. Xolair doses (milligrams per dose) administered by subcutaneous injection every 2&nbsp;weeks</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="10" style="vertical-align:bottom"><p><strong>Body weight (kg)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Baseline IgE (IU/ml)</strong></p></td><td style="vertical-align:bottom"><p>&sup3;20‑ 25*</p></td><td style="vertical-align:bottom"><p>&gt;25‑<br />30*</p></td><td style="vertical-align:bottom"><p>&gt;30‑<br />40</p></td><td style="vertical-align:bottom"><p>&gt;40‑<br />50</p></td><td style="vertical-align:bottom"><p>&gt;50‑<br />60</p></td><td style="vertical-align:bottom"><p>&gt;60‑<br />70</p></td><td style="vertical-align:bottom"><p>&gt;70‑<br />80</p></td><td style="vertical-align:bottom"><p>&gt;80‑<br />90</p></td><td style="vertical-align:bottom"><p>&gt;90‑<br />125</p></td><td style="vertical-align:bottom"><p>&gt;125‑<br />150</p></td></tr><tr><td style="vertical-align:top"><p>&sup3;30‑100</p></td><td colspan="5" rowspan="2" style="vertical-align:top"><p>ADMINISTRATION EVERY 4&nbsp;WEEKS</p><p>SEE TABLE&nbsp;2</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;100‑200</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;200‑300</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>375</p></td></tr><tr><td style="vertical-align:top"><p>&gt;300‑400</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>525</p></td></tr><tr><td style="vertical-align:top"><p>&gt;400‑500</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>525</p></td><td style="vertical-align:top"><p>600</p></td></tr><tr><td style="vertical-align:top"><p>&gt;500‑600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;600‑700</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>525</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;700‑800</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>525</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;800‑900</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>525</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;900-1000</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>525</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;1000-1100</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;1100-1200</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>525</p></td><td style="vertical-align:top"><p>600</p></td><td colspan="5" style="vertical-align:top"><p>Insufficient data to recommend a dose</p></td></tr><tr><td style="vertical-align:top"><p>&gt;1200-1300</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>525</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;1300-1500</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>525</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>*Body weights below 30&nbsp;kg were not studied in the pivotal trials for CRSwNP.</p><p><em>&nbsp;</em></p><p><em><u>Treatment duration, monitoring and dose adjustments</u></em></p><p><em>Allergic asthma</em></p><p>Xolair is intended for long-term treatment.<strong><em> </em></strong>Clinical trials have demonstrated that it takes at least 12‑16&nbsp;weeks for Xolair treatment to show effectiveness. At 16&nbsp;weeks after commencing Xolair therapy patients should be assessed by their physician for treatment effectiveness before further injections are administered. The decision to continue Xolair following the 16-week timepoint, or on subsequent occasions, should be based on whether a marked improvement in overall asthma control is seen (see section&nbsp;5.1, Physician&rsquo;s overall assessment of treatment effectiveness).</p><p>&nbsp;</p><p><em>Chronic rhinosinusitis with nasal polyps (CRSwNP)</em></p><p>In clinical trials for CRSwNP, changes in nasal polyps score (NPS) and nasal congestion score (NCS) were observed at 4 weeks. The need for continued therapy should be periodically reassessed based upon the patient&rsquo;s disease severity and level of symptom control.</p><p>&nbsp;</p><p><em>Allergic asthma and </em><em>chronic rhinosinusitis with nasal polyps (CRSwNP)</em></p><p>Discontinuation of Xolair treatment generally results in a return to elevated free IgE levels and associated symptoms. Total IgE levels are elevated during treatment and remain elevated for up to one year after the discontinuation of treatment. Therefore, re-testing of IgE levels during Xolair treatment cannot be used as a guide for dose determination. Dose determination after treatment interruptions lasting less than one year should be based on serum IgE levels obtained at the initial dose determination. Total serum IgE levels may be re-tested for dose determination if treatment with Xolair has been interrupted for one year or more.</p><p>&nbsp;</p><p>Doses should be adjusted for significant changes in body weight (see Tables&nbsp;2 and 3).</p><p>&nbsp;</p><p><em><u>Chronic spontaneous urticaria (CSU)</u></em></p><p>The recommended dose is 300&nbsp;mg by subcutaneous injection every four weeks.</p><p>&nbsp;</p><p>Prescribers are advised to periodically reassess the need for continued therapy.</p><p>&nbsp;</p><p>Clinical trial experience of long-term treatment in this indication is described in section&nbsp;5.1</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>Elderly (65&nbsp;years of age and older)</em></p><p>There are limited data available on the use of Xolair in patients older than 65&nbsp;years but there is no evidence that elderly patients require a different dose from younger adult patients.</p><p>&nbsp;</p><p><em>Renal or hepatic impairment</em></p><p>There have been no studies on the effect of impaired renal or hepatic function on the pharmacokinetics of omalizumab. Because omalizumab clearance at clinical doses is dominated by the reticular endothelial system (RES) it is unlikely to be altered by renal or hepatic impairment. While no particular dose adjustment is recommended for these patients, Xolair should be administered with caution (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>In allergic asthma, the safety and efficacy of Xolair in patients below the age of 6&nbsp;years have not been established. No data are available.</p><p>&nbsp;</p><p>In CRSwNP, the safety and efficacy of Xolair in patients below the age of 18&nbsp;years have not been established.</p><p>&nbsp;</p><p>In CSU, the safety and efficacy of Xolair in patients below the age of 12&nbsp;years have not been established.</p><p>&nbsp;</p><p><u>Method of a</u><u>dministration</u></p><p>&nbsp;</p><p>For subcutaneous administration only. Xolair must not be administered by the intravenous or intramuscular route.</p><p>&nbsp;</p><p>If more than one injection is needed to achieve the required dose, injections should be divided across two or more injection sites (Table 1).</p><p>&nbsp;</p><p>Patients with no known history of anaphylaxis may self-inject Xolair or be injected by a caregiver from the 4th dose onwards if a physician determines that this is appropriate (see section&nbsp;4.4). The patient or the caregiver must have been trained in the correct injection technique and the recognition of the early signs and symptoms of serious allergic reactions.</p><p>&nbsp;</p><p>Patients or caregivers should be instructed to inject the full amount of Xolair according to the instructions provided in the package leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>General</u></p><p>&nbsp;</p><p>Xolair is not indicated for the treatment of acute asthma exacerbations, acute bronchospasm or status asthmaticus.</p><p>&nbsp;</p><p>Xolair has not been studied in patients with hyperimmunoglobulin E syndrome or allergic bronchopulmonary aspergillosis or for the prevention of anaphylactic reactions, including those provoked by food allergy, atopic dermatitis, or allergic rhinitis. Xolair is not indicated for the treatment of these conditions.</p><p>&nbsp;</p><p>Xolair therapy has not been studied in patients with autoimmune diseases, immune complex-mediated conditions, or pre-existing renal or hepatic impairment (see section&nbsp;4.2). Caution should be exercised when administering Xolair in these patient populations.</p><p>&nbsp;</p><p>Abrupt discontinuation of systemic or inhaled corticosteroids after initiation of Xolair therapy in allergic asthma or CRSwNP is not recommended. Decreases in corticosteroids should be performed under the direct supervision of a physician and may need to be performed gradually.</p><p>&nbsp;</p><p><u>Immune system disorders</u></p><p>&nbsp;</p><p><em><u>Allergic reactions type&nbsp;I</u></em></p><p>Type&nbsp;I local or systemic allergic reactions, including anaphylaxis and anaphylactic shock, may occur when taking omalizumab, even after a long duration of treatment. However, most of these reactions occurred within 2&nbsp;hours after the first and subsequent injections of Xolair but some started beyond 2&nbsp;hours and even beyond 24&nbsp;hours after the injection. The majority of anaphylactic reactions occurred within the first 3&nbsp;doses of Xolair. Therefore, the first 3&nbsp;doses must be administered either by or under the supervision of a healthcare professional. A history of anaphylaxis unrelated to omalizumab may be a risk factor for anaphylaxis following Xolair administration. Therefore for patients with a known history of anaphylaxis, Xolair must be administered by a health care professional, who should always have medicinal products for the treatment of anaphylactic reactions available for immediate use following administration of Xolair. If an anaphylactic or other serious allergic reaction occurs, administration of Xolair must be discontinued immediately, and appropriate therapy initiated. Patients should be informed that such reactions are possible, and prompt medical attention should be sought if allergic reactions occur.</p><p>&nbsp;</p><p>Antibodies to omalizumab have been detected in a low number of patients in clinical trials (see section&nbsp;4.8). The clinical relevance of anti-Xolair antibodies is not well understood.</p><p>&nbsp;</p><p><em><u>Serum sickness</u></em></p><p>Serum sickness and serum sickness-like reactions, which are delayed allergic type&nbsp;III reactions, have been seen in patients treated with humanised monoclonal antibodies including omalizumab. The suggested pathophysiologic mechanism includes immune-complex formation and deposition due to development of antibodies against omalizumab. The onset has typically been 1‑5&nbsp;days after administration of the first or subsequent injections, also after long duration of treatment. Symptoms suggestive of serum sickness include arthritis/arthralgias, rash (urticaria or other forms), fever and lymphadenopathy. Antihistamines and corticosteroids may be useful for preventing or treating this disorder, and patients should be advised to report any suspected symptoms.</p><p>&nbsp;</p><p><em><u>Churg-Strauss syndrome and hypereosinophilic syndrome</u></em></p><p>Patients with severe asthma may rarely present systemic hypereosinophilic syndrome or allergic eosinophilic granulomatous vasculitis (Churg-Strauss syndrome), both of which are usually treated with systemic corticosteroids.</p><p>&nbsp;</p><p>In rare cases, patients on therapy with anti-asthma medicinal products, including omalizumab, may present or develop systemic eosinophilia and vasculitis. These events are commonly associated with the reduction of oral corticosteroid therapy.</p><p>&nbsp;</p><p>In these patients, physicians should be alert to the development of marked eosinophilia, vasculitic rash, worsening pulmonary symptoms, paranasal sinus abnormalities, cardiac complications, and/or neuropathy.</p><p>&nbsp;</p><p>Discontinuation of omalizumab should be considered in all severe cases with the above mentioned immune system disorders.</p><p>&nbsp;</p><p><u>Parasitic (helminth) infections</u></p><p>&nbsp;</p><p>IgE may be involved in the immunological response to some helminth infections. In patients at chronic high risk of helminth infection, a placebo-controlled trial in allergic patients showed a slight increase in infection rate with omalizumab, although the course, severity, and response to treatment of infection were unaltered. The helminth infection rate in the overall clinical programme, which was not designed to detect such infections, was less than 1 in 1,000&nbsp;patients. However, caution may be warranted in patients at high risk of helminth infection, in particular when travelling to areas where helminthic infections are endemic. If patients do not respond to recommended anti-helminth treatment, discontinuation of Xolair should be considered.</p><p>&nbsp;</p><p><u>Latex-sensitive individuals</u></p><p>&nbsp;</p><p>The removable needle cap of this pre‑filled syringe contains a derivative of natural rubber latex. No natural rubber latex has to date been detected in the removable needle cap. Nevertheless, the use of Xolair solution for injection in pre-filled syringe in latex-sensitive individuals has not been studied and thus there is a potential risk for hypersensitivity reactions which cannot be completely ruled out.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since IgE may be involved in the immunological response to some helminth infections, Xolair may indirectly reduce the efficacy of medicinal products for the treatment of helminthic or other parasitic infections (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Cytochrome P450 enzymes, efflux pumps and protein-binding mechanisms are not involved in the clearance of omalizumab; thus, there is little potential for drug-drug interactions. Medicinal product or vaccine interaction studies have not been performed with Xolair. There is no pharmacological reason to expect that commonly prescribed medicinal products used in the treatment of asthma, CRSwNP or CSU will interact with omalizumab.</p><p>&nbsp;</p><p><u>Allergic asthma</u></p><p>&nbsp;</p><p>In clinical studies Xolair was commonly used in conjunction with inhaled and oral corticosteroids, inhaled short-acting and long-acting beta agonists, leukotriene modifiers, theophyllines and oral antihistamines. There was no indication that the safety of Xolair was altered with these other commonly used anti-asthma medicinal products. Limited data are available on the use of Xolair in combination with specific immunotherapy (hypo-sensitisation therapy). In a clinical trial where Xolair was co-administered with immunotherapy, the safety and efficacy of Xolair in combination with specific immunotherapy were found to be no different to that of Xolair alone.</p><p>&nbsp;</p><p><u>Chronic rhinosinusitis with nasal polyps (CRSwNP)</u></p><p>&nbsp;</p><p>In clinical studies Xolair was used in conjunction with intranasal mometasone spray as per protocol. Other commonly used concomitant medicinal products included other intranasal corticosteroids, bronchodilators antihistamines, leukotriene receptor antagonists, adrenergics/sympathomimetics and local nasal anesthetics. There was no indication that the safety of Xolair was altered by the concomitant use of these other commonly used medicinal products.</p><p>&nbsp;</p><p><u>Chronic spontaneous urticaria (CSU)</u></p><p>&nbsp;</p><p>In clinical studies in CSU, Xolair was used in conjunction with antihistamines (anti-H1, anti-H2) and leukotriene receptor antagonists (LTRAs). There was no evidence that the safety of omalizumab was altered when used with these medicinal products relative to its known safety profile in allergic asthma. In addition, a population pharmacokinetic analysis showed no relevant effect of H2 antihistamines and LTRAs on omalizumab pharmacokinetics (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>Clinical studies in CSU included some patients aged 12 to 17&nbsp;years taking Xolair in conjunction with antihistamines (anti-H1, anti-H2) and LTRAs. No studies have been performed in children under 12&nbsp;years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>A moderate amount of data on pregnant women (between 300‑1,000&nbsp;pregnancy outcomes) based on pregnancy registry and post-marketing spontaneous reports, indicates no malformative or foeto/neonatal toxicity. A prospective pregnancy registry study (EXPECT) in 250&nbsp;pregnant women with asthma exposed to Xolair showed the prevalence of major congenital anomalies was similar (8.1% vs. 8.9%) between EXPECT and disease‑matched (moderate and severe asthma) patients. The interpretation of data may be impacted due to methodological limitations of the study, including small sample size and non-randomised design.</p><p>&nbsp;</p><p>Omalizumab crosses the placental barrier. However, animal studies do not indicate either direct or indirect harmful effects with respect to reproductive toxicity (see section&nbsp;5.3).</p><p>&nbsp;</p><p>Omalizumab has been associated with age-dependent decreases in blood platelets in non-human primates, with a greater relative sensitivity in juvenile animals (see section&nbsp;5.3).</p><p>&nbsp;</p><p>If clinically needed, the use of Xolair may be considered during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Immunoglobulins G (IgGs) are present in human milk and therefore it is expected that omalizumab will be present in human milk. Available data in non-human primates have shown excretion of omalizumab into milk (see section&nbsp;5.3).</p><p>&nbsp;</p><p>The EXPECT study, with 154&nbsp;infants who had been exposed to Xolair during pregnancy and through breast-feeding did not indicate adverse effects on the breast-fed infant. The interpretation of data may be impacted due to methodological limitations of the study, including small sample size and non-randomised design.</p><p>&nbsp;</p><p>Given orally, immunoglobulin G proteins undergo intestinal proteolysis and have poor bioavailability. No effects on the breast-fed newborns/infants are anticipated. Consequently, if clinically needed, the use of Xolair may be considered during breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are no human fertility data for omalizumab. In specifically-designed non-clinical fertility studies, in non-human primates including mating studies, no impairment of male or female fertility was observed following repeated dosing with omalizumab at dose levels up to 75&nbsp;mg/kg. Furthermore, no genotoxic effects were observed in a separate non-clinical genotoxicity study.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Xolair has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)</u></p><p>&nbsp;</p><p><em><u>Summary of the safety profile</u></em></p><p>&nbsp;</p><p>During allergic asthma clinical trials in adult and adolescent patients 12&nbsp;years of age and older, the most commonly reported adverse reactions were headaches and injection site reactions, including injection site pain, swelling, erythema and pruritus. In clinical trials in children 6 to &lt;12&nbsp;years of age, the most commonly reported adverse reactions were headache, pyrexia and upper abdominal pain. Most of the reactions were mild or moderate in severity. In clinical trials in patients &ge;18&nbsp;years of age in CRSwNP, the most commonly reported adverse reactions were headache, dizziness, arthralgia, abdominal pain upper and injection site reactions.</p><p>&nbsp;</p><p><em><u>Tabulated list of adverse reactions</u></em></p><p>&nbsp;</p><p>Table&nbsp;4 lists the adverse reactions recorded in clinical studies in the total allergic asthma and CRSwNP safety population treated with Xolair by MedDRA system organ class and frequency. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. Frequency categories are defined as: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000). Reactions reported in the post-marketing setting are listed with frequency not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>Table&nbsp;4 </strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions in allergic asthma and CRSwNP</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pharyngitis</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Parasitic infection</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Idiopathic thrombocytopenia, including severe cases</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaphylactic reaction, other serious allergic conditions, anti-omalizumab antibody development</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Serum sickness, may include fever and lymphadenopathy</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Headache*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Syncope, paraesthesia, somnolence, dizziness<sup>#</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Postural hypotension, flushing</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Allergic bronchospasm, coughing</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Laryngoedema</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Allergic granulomatous vasculitis (i.e. Churg-Strauss syndrome)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Abdominal pain upper**<sup>,</sup><sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dyspeptic signs and symptoms, diarrhoea, nausea</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Photosensitivity, urticaria, rash, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Alopecia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Arthralgia&dagger;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Systemic lupus erythematosus (SLE)</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Myalgia, joint swelling</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Pyrexia**</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Injection site reactions such as swelling, erythema, pain, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Influenza-like illness, swelling arms, weight increase, fatigue</p></td></tr></tbody></table><p>*: Very common in children 6 to &lt;12&nbsp;years of age</p><p>**: In children 6 to &lt;12&nbsp;years of age</p><p><sup>#</sup>: Common in nasal polyp trials</p><p>&dagger;: Unknown in allergic asthma trials</p><p>&nbsp;</p><p><u>Chronic spontaneous urticaria (CSU)</u></p><p>&nbsp;</p><p><em><u>Summary of the safety profile</u></em></p><p>The safety and tolerability of omalizumab were investigated with doses of 75&nbsp;mg, 150&nbsp;mg and 300&nbsp;mg every four weeks in 975&nbsp;CSU patients, 242 of whom received placebo. Overall, 733&nbsp;patients were treated with omalizumab for up to 12&nbsp;weeks and 490&nbsp;patients for up to 24&nbsp;weeks. Of those, 412&nbsp;patients were treated for up to 12&nbsp;weeks and 333&nbsp;patients were treated for up to 24&nbsp;weeks at the 300&nbsp;mg dose.</p><p>&nbsp;</p><p><em><u>Tabulated list of adverse reactions</u></em></p><p>A separate table (Table&nbsp;5) shows the adverse reactions for the CSU indication resulting from differences in dosages and treatment populations (with significantly different risk factors, comorbidities, co-medications and ages [e.g. asthma trials included children from 6‑12&nbsp;years of age]).</p><p>&nbsp;</p><p>Table&nbsp;5 lists the adverse reactions (events occurring in &ge;1% of patients in any treatment group and &ge;2% more frequently in any omalizumab treatment group than with placebo (after medical review)) reported with 300&nbsp;mg in the three pooled phase III studies. The adverse reactions presented are divided into two groups: those identified in the 12‑week and the 24‑week treatment periods.</p><p>&nbsp;</p><p>The adverse reactions are listed by MedDRA system organ class. Within each system organ class, the adverse reactions are ranked by frequency, with the most frequent reactions listed first. The corresponding frequency category for each adverse reaction is based on the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1000); very rare (&lt;1/10,000) and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>Table&nbsp;5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions from the pooled CSU safety database (day&nbsp;1 to week&nbsp;24) at 300&nbsp;mg omalizumab</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2"><p><strong>12-Week</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Omalizumab studies 1, 2 and 3 Pooled</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category</strong></p></td></tr><tr><td style="vertical-align:top"><p>Placebo N=242</p></td><td><p>300&nbsp;mg N=412</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td><p>Sinusitis</p></td><td style="vertical-align:top"><p>5 (2.1%)</p></td><td><p>20 (4.9%)</p></td><td><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td><p>Headache</p></td><td style="vertical-align:top"><p>7 (2.9%)</p></td><td><p>25 (6.1%)</p></td><td><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td><p>Arthralgia</p></td><td style="vertical-align:top"><p>1 (0.4%)</p></td><td><p>12 (2.9%)</p></td><td><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>General disorder and administration site conditions</strong></p></td></tr><tr><td><p>Injection site reaction*</p></td><td><p>2 (0.8%)</p></td><td><p>11 (2.7%)</p></td><td><p>Common</p></td></tr><tr><td rowspan="2"><p><strong>24-Week</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Omalizumab studies 1 and 3 Pooled</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category</strong></p></td></tr><tr><td style="vertical-align:top"><p>Placebo N=163</p></td><td><p>300&nbsp;mg N=333</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td><p>Upper respiratory tract infection</p></td><td><p>5 (3.1%)</p></td><td><p>19 (5.7%)</p></td><td><p>Common</p></td></tr></tbody></table><p>* Despite not showing a 2% difference to placebo, injection site reactions were included as all cases were assessed causally related to study treatment.</p><p>&nbsp;</p><p>In a 48 week study, 81 CSU patients received omalizumab 300 mg every 4 weeks (see section 5.1). The safety profile of long-term use was similar to the safety profile observed in 24-week studies in CSU.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em><u>Immune system disorders</u></em></p><p>For further information, see section&nbsp;4.4.</p><p>&nbsp;</p><p><em><u>Anaphylaxis</u></em></p><p>Anaphylactic reactions were rare in clinical trials. However, post-marketing data following a cumulative search in the safety database retrieved a total of 898 anaphylaxis cases. Based on an estimated exposure of 566,923 patient treatment years, this results in a reporting rate of approximately 0.20%.</p><p>&nbsp;</p><p><em><u>Arterial thromboembolic events (ATE)</u></em></p><p>In controlled clinical trials and during interim analyses of an observational study, a numerical imbalance of ATE was observed. The definition of the composite endpoint ATE included stroke, transient ischaemic attack, myocardial infarction, unstable angina, and cardiovascular death (including death from unknown cause). In the final analysis of the observational study, the rate of ATE per 1,000 patient years was 7.52 (115/15,286 patient years) for Xolair-treated patients and 5.12 (51/9,963 patient years) for control patients. In a multivariate analysis controlling for available baseline cardiovascular risk factors, the hazard ratio was 1.32 (95% confidence interval 0.91‑1.91). In a separate analysis of pooled clinical trials, which included all randomised double-blind, placebo-controlled clinical trials lasting 8 or more weeks, the rate of ATE per 1,000 patient years was 2.69 (5/1,856 patient years) for Xolair-treated patients and 2.38 (4/1,680 patient years) for placebo patients (rate ratio 1.13, 95% confidence interval 0.24‑5.71).</p><p>&nbsp;</p><p><em><u>Platelets</u></em></p><p>In clinical trials few patients had platelet counts below the lower limit of the normal laboratory range. None of these changes were associated with bleeding episodes or a decrease in haemoglobin. No pattern of persistent decrease in platelet counts, as observed in non-human primates (see section&nbsp;5.3), has been reported in humans (patients above 6&nbsp;years of age), even though isolated cases of idiopathic thrombocytopenia, including severe cases, have been reported in the post-marketing setting.</p><p>&nbsp;</p><p><em><u>Parasitic infections</u></em></p><p>In allergic patients at chronic high risk of helminth infection, a placebo-controlled trial showed a slight numerical increase in infection rate with omalizumab that was not statistically significant. The course, severity, and response to treatment of infections were unaltered (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em><u>Systemic lupus erythematosus</u></em></p><p>Clinical trial and post-marketing cases of systemic lupus erythematosus (SLE) have been reported in patients with moderate to severe asthma and CSU. The pathogenesis of SLE is not well understood.</p><p>&nbsp;</p><p><u>To report any side effect(s):</u></p><p>&bull;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>o Fax: +966112057662</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Maximum tolerated dose of Xolair has not been determined. Single intravenous doses up to 4,000&nbsp;mg have been administered to patients without evidence of dose-limiting toxicities. The highest cumulative dose administered to patients was 44,000&nbsp;mg over a 20‑week period and this dose did not result in any untoward acute effects.</p><p>&nbsp;</p><p>If an overdose is suspected, the patient should be monitored for any abnormal signs or symptoms. Medical treatment should be sought and instituted appropriately.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for obstructive airway diseases, other systemic drugs for obstructive airway diseases, ATC code: R03DX05</p><p>&nbsp;</p><p>Omalizumab is a recombinant DNA-derived humanised monoclonal antibody that selectively binds to human immunoglobulin E (IgE). The antibody is an IgG1 kappa that contains human framework regions with the complementary-determining regions of a murine parent antibody that binds to IgE.</p><p><u>Allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)</u></p><p>&nbsp;</p><p><em><u>Mechanism of action</u></em></p><p>Omalizumab binds to IgE and prevents binding of IgE to FceRI (high-affinity IgE receptor) on basophils and mast cells, thereby reducing the amount of free IgE that is available to trigger the allergic cascade. Treatment of atopic subjects with omalizumab resulted in a marked down-regulation of FceRI receptors on basophils. Treatment with Xolair inhibits IgE-mediated inflammation, as evidenced by reduced blood and tissue eosinophils and reduced inflammatory mediators, including IL‑4, IL-5, and IL-13 by innate, adaptive and non-immune cells.</p><p>&nbsp;</p><p><em><u>Pharmacodynamic effects</u></em></p><p><em>Allergic asthma</em></p><p>The <em>in vitro</em> histamine release from basophils isolated from Xolair-treated subjects was reduced by approximately 90% following stimulation with an allergen compared to pre-treatment values.</p><p>&nbsp;</p><p>In clinical studies in allergic asthma patients, serum free IgE levels were reduced in a dose-dependent manner within one hour following the first dose and maintained between doses. One year after discontinuation of Xolair dosing, the IgE levels had returned to pre-treatment levels with no observed rebound in IgE levels after washout of the medicinal product.</p><p>&nbsp;</p><p><em><u>Chronic rhinosinusitis with nasal polyps (CRSwNP)</u></em></p><p>In clinical studies in patients with CRSwNP, Xolair treatment led to a reduction in serum free IgE (approx. 95%) and an increase in serum total IgE levels, to a similar extent as observed in patients with allergic asthma. Total IgE levels in serum increased due to the formation of omalizumab‑IgE complexes that have a slower elimination rate compared with free IgE.</p><p>&nbsp;</p><p><u>Chronic spontaneous urticaria (CSU)</u></p><p>&nbsp;</p><p><em><u>Mechanism of action</u></em></p><p>Omalizumab binds to IgE and lowers free IgE levels. Subsequently, IgE receptors (Fc&epsilon;RI) on cells down-regulate. It is not entirely understood<em> </em>how this results in an improvement of CSU symptoms.</p><p>&nbsp;</p><p><em><u>Pharmacodynamic effects</u></em></p><p>In clinical studies in CSU patients, maximum suppression of free IgE was observed 3&nbsp;days after the first subcutaneous dose. After repeated dosing once every 4&nbsp;weeks, pre-dose serum free IgE levels remained stable between 12 and 24&nbsp;weeks of treatment. After discontinuation of Xolair, free IgE levels increased towards pre-treatment levels over a 16‑week treatment-free follow-up period.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em><u>Allergic asthma</u></em></p><p><em>Adults and adolescents &ge;12&nbsp;years of age</em></p><p>The efficacy and safety of Xolair were demonstrated in a 28-week double-blind placebo-controlled study (study&nbsp;1) involving 419&nbsp;severe allergic asthmatics, ages 12‑79&nbsp;years, who had reduced lung function (FEV<sub>1</sub> 40‑80% predicted) and poor asthma symptom control despite receiving high dose inhaled corticosteroids and a long-acting beta2-agonist. Eligible patients had experienced multiple asthma exacerbations requiring systemic corticosteroid treatment or had been hospitalised or attended an emergency room due to a severe asthma exacerbation in the past year despite continuous treatment with high-dose inhaled corticosteroids and a long-acting beta2-agonist. Subcutaneous Xolair or placebo were administered as add-on therapy to</p><p>&gt;1,000&nbsp;micrograms beclomethasone dipropionate (or equivalent) plus a long-acting beta2-agonist. Oral corticosteroid, theophylline and leukotriene-modifier maintenance therapies were allowed (22%, 27%, and 35% of patients, respectively).</p><p>&nbsp;</p><p>The rate of asthma exacerbations requiring treatment with bursts of systemic corticosteroids was the primary endpoint. Omalizumab reduced the rate of asthma exacerbations by 19% (p = 0.153). Further evaluations which did show statistical significance (p&lt;0.05) in favour of Xolair included reductions in severe exacerbations (where patient&rsquo;s lung function was reduced to below 60% of personal best and requiring systemic corticosteroids) and asthma-related emergency visits (comprised of hospitalisations, emergency room, and unscheduled doctor visits), and improvements in Physician&rsquo;s overall assessment of treatment effectiveness, Asthma-related Quality of Life (AQL), asthma symptoms and lung function.</p><p>&nbsp;</p><p>In a subgroup analysis, patients with pre-treatment total IgE &ge;76&nbsp;IU/ml were more likely to experience clinically meaningful benefit to Xolair. In these patients in study&nbsp;1 Xolair reduced the rate of asthma exacerbations by 40% (p = 0.002). In addition more patients had clinically meaningful responses in the total IgE &ge;76&nbsp;IU/ml population across the Xolair severe asthma programme. Table&nbsp;6 includes results in the study&nbsp;1 population.</p><p>&nbsp;</p><p><strong>Table&nbsp;6</strong><strong> Results of study&nbsp;1</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Whole study&nbsp;1 population</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Xolair</p><p>N=209</p></td><td style="vertical-align:top"><p>Placebo</p><p>N=210</p></td></tr><tr><td style="vertical-align:top"><p><strong>Asthma exacerbations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rate per 28-week period</p></td><td style="vertical-align:top"><p>0.74</p></td><td style="vertical-align:top"><p>0.92</p></td></tr><tr><td style="vertical-align:top"><p>% reduction, p-value for rate ratio</p></td><td colspan="2" style="vertical-align:top"><p>19.4%, p = 0.153</p></td></tr><tr><td style="vertical-align:top"><p><strong>Severe asthma exacerbations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rate per 28-week period</p></td><td style="vertical-align:top"><p>0.24</p></td><td style="vertical-align:top"><p>0.48</p></td></tr><tr><td style="vertical-align:top"><p>% reduction, p-value for rate ratio</p></td><td colspan="2" style="vertical-align:top"><p>50.1%, p = 0.002</p></td></tr><tr><td style="vertical-align:top"><p><strong>Emergency visits</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rate per 28-week period</p></td><td style="vertical-align:top"><p>0.24</p></td><td style="vertical-align:top"><p>0.43</p></td></tr><tr><td style="vertical-align:top"><p>% reduction, p-value for rate ratio</p></td><td colspan="2" style="vertical-align:top"><p>43.9%, p = 0.038</p></td></tr><tr><td style="vertical-align:top"><p><strong>Physician&rsquo;s overall assessment</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>% responders*</p></td><td style="vertical-align:top"><p>60.5%</p></td><td style="vertical-align:top"><p>42.8%</p></td></tr><tr><td style="vertical-align:top"><p>p-value**</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p><strong>AQL improvement</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>% of patients &ge;0.5 improvement</p></td><td style="vertical-align:top"><p>60.8%</p></td><td style="vertical-align:top"><p>47.8%</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.008</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; marked improvement or complete control</p><p>**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p-value for overall distribution of assessment</p><p>&nbsp;</p><p>Study&nbsp;2 assessed the efficacy and safety of Xolair in a population of 312&nbsp;severe allergic asthmatics which matched the population in study&nbsp;1. Treatment with Xolair in this open label study led to a 61% reduction in clinically significant asthma exacerbation rate compared to current asthma therapy alone.</p><p>&nbsp;</p><p>Four additional large placebo-controlled supportive studies of 28 to 52&nbsp;weeks duration in 1,722&nbsp;adults and adolescents (studies&nbsp;3, 4, 5, 6) assessed the efficacy and safety of Xolair in patients with severe persistent asthma. Most patients were inadequately controlled but were</p><p>receiving less concomitant asthma therapy than patients in studies&nbsp;1 or 2. Studies&nbsp;3‑5 used exacerbation as primary endpoint, whereas study&nbsp;6 primarily evaluated inhaled corticosteroid sparing.</p><p>&nbsp;</p><p>In studies&nbsp;3, 4 and 5 patients treated with Xolair had respective reductions in asthma exacerbation rates of 37.5% (p = 0.027), 40.3% (p&lt;0.001) and 57.6% (p&lt;0.001) compared to placebo.</p><p>&nbsp;</p><p>In study&nbsp;6, significantly more severe allergic asthma patients on Xolair were able to reduce their fluticasone dose to &pound;500&nbsp;micrograms/day without deterioration of asthma control (60.3%) compared to the placebo group (45.8%, p&lt;0.05).</p><p>&nbsp;</p><p>Quality of life scores were measured using the Juniper Asthma-related Quality of Life Questionnaire. For all six studies there was a statistically significant improvement from baseline in quality of life scores for Xolair patients versus the placebo or control group.</p><p>&nbsp;</p><p>Physician&rsquo;s overall assessment of treatment effectiveness:</p><p>Physician&rsquo;s overall assessment was performed in five of the above studies as a broad measure of asthma control performed by the treating physician. The physician was able to take into account PEF (peak expiratory flow), day and night time symptoms, rescue medication use, spirometry and exacerbations. In all five studies a significantly greater proportion of Xolair treated patients were judged to have achieved either a marked improvement or complete control of their asthma compared to placebo patients.</p><p>&nbsp;</p><p><em>Children 6 to &lt;12&nbsp;years of age</em></p><p>The primary support for safety and efficacy of Xolair in the group aged 6 to &lt;12&nbsp;years comes from one randomised, double-blind, placebo-controlled, multi-centre trial (study&nbsp;7).</p><p>&nbsp;</p><p>Study&nbsp;7 was a placebo-controlled trial which included a specific subgroup (n=235) of patients as defined in the present indication, who were treated with high-dose inhaled corticosteroids (&ge;500&nbsp;&micro;g/day fluticasone equivalent) plus long-acting beta agonist.</p><p>&nbsp;</p><p>A clinically significant exacerbation was defined as a worsening of asthma symptoms as judged clinically by the investigator, requiring doubling of the baseline inhaled corticosteroid dose for at least 3&nbsp;days and/or treatment with rescue systemic (oral or intravenous) corticosteroids for at least 3&nbsp;days.</p><p>&nbsp;</p><p>In the specific subgroup of patients on high dose inhaled corticosteroids, the omalizumab group had a statistically significantly lower rate of clinically significant asthma exacerbations than the placebo group. At 24&nbsp;weeks, the difference in rates between treatment groups represented a 34% (rate ratio 0.662, p = 0.047) decrease relative to placebo for omalizumab patients. In the second double-blind 28-week treatment period the difference in rates between treatment groups represented a 63% (rate ratio 0.37, p&lt;0.001) decrease relative to placebo for omalizumab patients.</p><p>&nbsp;</p><p>During the 52-week double-blind treatment period (including the 24-week fixed-dose steroid phase and the 28-week steroid adjustment phase) the difference in rates between treatment groups represented a 50% (rate ratio 0.504, p&lt;0.001) relative decrease in exacerbations for omalizumab patients.</p><p>&nbsp;</p><p>The omalizumab group showed greater decreases in beta-agonist rescue medication use than the placebo group at the end of the 52-week treatment period, although the difference between</p><p>treatment groups was not statistically significant. For the global evaluation of treatment effectiveness at the end of the 52-week double-blind treatment period in the subgroup of severe patients on high-dose inhaled corticosteroids plus long-acting beta agonists, the proportion of patients rated as having &lsquo;excellent&rsquo; treatment effectiveness was higher, and the proportions having &lsquo;moderate&rsquo; or &lsquo;poor&rsquo; treatment effectiveness lower in the omalizumab group compared to the placebo group; the difference between groups was statistically significant (p&lt;0.001), while there were no differences between the omalizumab and placebo groups for patients&rsquo; subjective Quality of Life ratings.</p><p>&nbsp;</p><p><em><u>Chronic rhinosinusitis with nasal polyps (CRSwNP)</u></em></p><p>The safety and efficacy of Xolair were evaluated in two randomised, double-blind, placebo-controlled trials in patients with CRSwNP (Table&nbsp;8). Patients received Xolair or placebo subcutaneously every 2 or 4&nbsp;weeks (see section&nbsp;4.2). All patients received background intranasal mometasone therapy throughout the study. Prior sino-nasal surgery or prior systemic corticosteroid usage were not required for inclusion in the studies. Patients received Xolair or placebo for 24&nbsp;weeks followed by a 4-week follow-up period. Demographics and baseline characteristics, including allergic comorbidities, are described in Table&nbsp;7.</p><p>&nbsp;</p><p><strong>Table&nbsp;7</strong><strong> Demographics and baseline characteristics of nasal polyp studies</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Nasal polyp study&nbsp;1</strong></p><p><strong>N=138</strong></p></td><td style="vertical-align:top"><p><strong>Nasal polyp study&nbsp;2</strong></p><p><strong>N=127</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean age (years) (SD)</p></td><td style="vertical-align:top"><p>51.0 (13.2)</p></td><td style="vertical-align:top"><p>50.1 (11.9)</p></td></tr><tr><td style="vertical-align:top"><p>% Male</p></td><td style="vertical-align:top"><p>63.8</p></td><td style="vertical-align:top"><p>65.4</p></td></tr><tr><td style="vertical-align:top"><p>Patients with systemic corticosteroid use in the previous year (%)</p></td><td style="vertical-align:top"><p>18.8</p></td><td style="vertical-align:top"><p>26.0</p></td></tr><tr><td style="vertical-align:top"><p>Bilateral endoscopic nasal polyp score (NPS): mean (SD), range 0-8</p></td><td style="vertical-align:top"><p>6.2 (1.0)</p></td><td style="vertical-align:top"><p>6.3 (0.9)</p></td></tr><tr><td style="vertical-align:top"><p>Nasal congestion score (NCS): mean (SD), range 0-3</p></td><td style="vertical-align:top"><p>2.4 (0.6)</p></td><td style="vertical-align:top"><p>2.3 (0.7)</p></td></tr><tr><td style="vertical-align:top"><p>Sense of smell score: mean (SD), range 0-3</p></td><td style="vertical-align:top"><p>2.7 (0.7)</p></td><td style="vertical-align:top"><p>2.7 (0.7)</p></td></tr><tr><td style="vertical-align:top"><p>SNOT-22 total score: mean (SD) range 0-110</p></td><td style="vertical-align:top"><p>60.1 (17.7)</p></td><td style="vertical-align:top"><p>59.5 (19.3)</p></td></tr><tr><td style="vertical-align:top"><p>Blood eosinophils (cells/&micro;l): mean (SD)</p></td><td style="vertical-align:top"><p>346.1 (284.1)</p></td><td style="vertical-align:top"><p>334.6 (187.6)</p></td></tr><tr><td style="vertical-align:top"><p>Total IgE IU/ml: mean (SD)</p></td><td style="vertical-align:top"><p>160.9 (139.6)</p></td><td style="vertical-align:top"><p>190.2 (200.5)</p></td></tr><tr><td style="vertical-align:top"><p>Asthma (%)</p></td><td style="vertical-align:top"><p>53.6</p></td><td style="vertical-align:top"><p>60.6</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Mild (%)</p></td><td style="vertical-align:top"><p>37.8</p></td><td style="vertical-align:top"><p>32.5</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Moderate (%)</p></td><td style="vertical-align:top"><p>58.1</p></td><td style="vertical-align:top"><p>58.4</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Severe (%)</p></td><td style="vertical-align:top"><p>4.1</p></td><td style="vertical-align:top"><p>9.1</p></td></tr><tr><td style="vertical-align:top"><p>Aspirin exacerbated respiratory disease (%)</p></td><td style="vertical-align:top"><p>19.6</p></td><td style="vertical-align:top"><p>35.4</p></td></tr><tr><td style="vertical-align:top"><p>Allergic rhinitis</p></td><td style="vertical-align:top"><p>43.5</p></td><td style="vertical-align:top"><p>42.5</p></td></tr></tbody></table><p>SD = standard deviation; SNOT-22 = Sino-Nasal Outcome Test 22 Questionnaire; IgE = Immunoglobulin E; IU = international units. For NPS, NCS, and SNOT-22 higher scores indicate greater disease severity.</p><p>The co-primary endpoints were bilateral nasal polyps score (NPS) and average daily nasal congestion score (NCS) at Week&nbsp;24. In both nasal polyp studies&nbsp;1 and 2, patients who received Xolair had statistically significant greater improvements from baseline at Week&nbsp;24 in NPS and weekly average NCS than patients who received placebo. Results from nasal polyp studies&nbsp;1 and 2 are shown in Table&nbsp;8.</p><p><strong>Table&nbsp;8</strong><strong> Change from baseline at Week&nbsp;24 in clinical scores from nasal polyp study</strong><strong>&nbsp;</strong><strong>1, nasal polyp study</strong><strong>&nbsp;</strong><strong>2, and pooled data</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Nasal polyp<br />study&nbsp;1</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Nasal polyp<br />study&nbsp;2</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Nasal polyp<br />pooled results</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>Placebo</strong></p></td><td style="vertical-align:bottom"><p><strong>Xolair</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo</strong></p></td><td style="vertical-align:bottom"><p><strong>Xolair</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Xolair</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>66</p></td><td style="vertical-align:top"><p>72</p></td><td style="vertical-align:top"><p>65</p></td><td style="vertical-align:top"><p>62</p></td><td style="vertical-align:top"><p>131</p></td><td style="vertical-align:top"><p>134</p></td></tr><tr><td style="vertical-align:top"><p>Nasal polyp score</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline mean</p></td><td style="vertical-align:top"><p>6.32</p></td><td style="vertical-align:top"><p>6.19</p></td><td style="vertical-align:top"><p>6.09</p></td><td style="vertical-align:top"><p>6.44</p></td><td style="vertical-align:top"><p>6.21</p></td><td style="vertical-align:top"><p>6.31</p></td></tr><tr><td style="vertical-align:top"><p>LS mean change at Week&nbsp;24</p></td><td style="vertical-align:top"><p>0.06</p></td><td style="vertical-align:top"><p>-1.08</p></td><td style="vertical-align:top"><p>-0.31</p></td><td style="vertical-align:top"><p>-0.90</p></td><td style="vertical-align:top"><p>-0.13</p></td><td style="vertical-align:top"><p>-0.99</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95%) CI<sup> </sup></p></td><td colspan="2" style="vertical-align:top"><p>-1.14 (-1.59, -069)</p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>-0.59 (-1.05, -012)</p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>-0.86 (-1.18, -0.54)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td><td colspan="2" style="vertical-align:top"><p>0.0140</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td><p>7-day average of daily nasal congestion score</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline mean</p></td><td style="vertical-align:top"><p>2.46</p></td><td style="vertical-align:top"><p>2.40</p></td><td style="vertical-align:top"><p>2.29</p></td><td style="vertical-align:top"><p>2.26</p></td><td style="vertical-align:top"><p>2.38</p></td><td style="vertical-align:top"><p>2.34</p></td></tr><tr><td style="vertical-align:top"><p>LS mean change at Week&nbsp;24</p></td><td style="vertical-align:top"><p>-0.35</p></td><td style="vertical-align:top"><p>-0.89</p></td><td style="vertical-align:top"><p>-0.20</p></td><td style="vertical-align:top"><p>-0.70</p></td><td style="vertical-align:top"><p>-0.28</p></td><td style="vertical-align:top"><p>-0.80</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95%) CI</p></td><td colspan="2" style="vertical-align:top"><p>-0.55 (-0.84, -0.25)</p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>-0.50 (-0.80, -0.19)</p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>-0.52 (-0.73, -0.31)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.0004</p></td><td colspan="2" style="vertical-align:top"><p>0.0017</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>TNSS</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline mean</p></td><td style="vertical-align:top"><p>9.33</p></td><td style="vertical-align:top"><p>8.56</p></td><td style="vertical-align:top"><p>8.73</p></td><td style="vertical-align:top"><p>8.37</p></td><td style="vertical-align:top"><p>9.03</p></td><td style="vertical-align:top"><p>8.47</p></td></tr><tr><td style="vertical-align:top"><p>LS mean change at Week&nbsp;24</p></td><td style="vertical-align:top"><p>-1.06</p></td><td style="vertical-align:top"><p>-2.97</p></td><td style="vertical-align:top"><p>-0.44</p></td><td style="vertical-align:top"><p>-2.53</p></td><td style="vertical-align:top"><p>-0.77</p></td><td style="vertical-align:top"><p>-2.75</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95%)</p></td><td colspan="2" style="vertical-align:top"><p>-1.91 (-2.85, -0.96)</p></td><td colspan="2" style="vertical-align:top"><p>-2.09 (-3.00, -1.18)</p></td><td colspan="2" style="vertical-align:top"><p>-1.98 (-2.63, -1.33)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.0001</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>SNOT-22</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline mean</p></td><td style="vertical-align:top"><p>60.26</p></td><td style="vertical-align:top"><p>59.82</p></td><td style="vertical-align:top"><p>59.80</p></td><td style="vertical-align:top"><p>59.21</p></td><td style="vertical-align:top"><p>60.03</p></td><td style="vertical-align:top"><p>59.54</p></td></tr><tr><td style="vertical-align:top"><p>LS mean change at Week&nbsp;24</p></td><td style="vertical-align:top"><p>-8.58</p></td><td style="vertical-align:top"><p>-24.70</p></td><td style="vertical-align:top"><p>-6.55</p></td><td style="vertical-align:top"><p>-21.59</p></td><td style="vertical-align:top"><p>-7.73</p></td><td style="vertical-align:top"><p>-23.10</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95%)</p></td><td colspan="2" style="vertical-align:top"><p>-16.12 (-21.86, -10.38)</p></td><td colspan="2" style="vertical-align:top"><p>-15.04 (-21.26, -8.82)</p></td><td colspan="2" style="vertical-align:top"><p>-15.36 (-19.57, -11.16)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>(MID = 8.9)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>UPSIT</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline mean</p></td><td style="vertical-align:top"><p>13.56</p></td><td style="vertical-align:top"><p>12.78</p></td><td style="vertical-align:top"><p>13.27</p></td><td style="vertical-align:top"><p>12.87</p></td><td style="vertical-align:top"><p>13.41</p></td><td style="vertical-align:top"><p>12.82</p></td></tr><tr><td style="vertical-align:top"><p>LS mean change at Week&nbsp;24</p></td><td style="vertical-align:top"><p>0.63</p></td><td style="vertical-align:top"><p>4.44</p></td><td style="vertical-align:top"><p>0.44</p></td><td style="vertical-align:top"><p>4.31</p></td><td style="vertical-align:top"><p>0.54</p></td><td style="vertical-align:top"><p>4.38</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95%)</p></td><td colspan="2" style="vertical-align:top"><p>3.81 (1.38, 6.24)</p></td><td colspan="2" style="vertical-align:top"><p>3.86 (1.57, 6.15)</p></td><td colspan="2" style="vertical-align:top"><p>3.84 (2.17, 5.51)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.0024</p></td><td colspan="2" style="vertical-align:top"><p>0.0011</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr></tbody></table><p>LS=least-square; CI = confidence interval; TNSS = Total nasal symptom score; SNOT-22 = Sino-Nasal Outcome Test 22 Questionnaire; UPSIT = University of Pennsylvania Smell Identification Test; MID = minimal important difference.</p><p>&nbsp;</p><p><img alt="" width="792" height="438" src="data:image/png;base64,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" /></p><p>In a pre-specified pooled analysis of rescue treatment (systemic corticosteroids for &sup3;3&nbsp;consecutive days or nasal polypectomy) during the 24-week treatment period, the proportion of patients requiring rescue treatment was lower in Xolair compared to placebo (2.3% versus 6.2%, respectively). The odds-ratio of having taken rescue treatment in Xolair compared to placebo was 0.38 (95% CI: 0.10, 1.49). There were no sino-nasal surgeries reported in either study.</p><p>The long-term efficacy and safety of Xolair in patients with CRSwNP who had participated in nasal polyp studies&nbsp;1 and 2 was assessed in an open-label extension study. Efficacy data from this study suggest that clinical benefit provided at Week&nbsp;24 was sustained through to Week&nbsp;52. Safety data were overall consistent with the known safety profile of omalizumab.</p><p><u>C</u><u>hronic spontaneous urticaria (CSU)</u></p><p>&nbsp;</p><p>The efficacy and safety of Xolair were demonstrated in two randomised, placebo-controlled phase III studies (study&nbsp;1 and 2) in patients with CSU who remained symptomatic despite H1 antihistamine therapy at the approved dose. A third study (study&nbsp;3) primarily evaluated the safety of Xolair in patients with CSU who remained symptomatic despite treatment with H1 antihistamines at up to four times the approved dose and H2 antihistamine and/or LTRA treatment. The three studies enrolled 975&nbsp;patients aged between 12 and 75&nbsp;years (mean age 42.3&nbsp;years; 39&nbsp;patients 12‑17&nbsp;years, 54&nbsp;patients &ge;65&nbsp;years; 259&nbsp;males and 716&nbsp;females). All patients were required to have inadequate symptom control, as assessed by a weekly urticaria activity score (UAS7, range 0‑42) of &ge;16, and a weekly itch severity score (which is a component of the UAS7; range 0‑21) of &ge;8 for the 7&nbsp;days prior to randomisation, despite having used an antihistamine for at least 2&nbsp;weeks beforehand.</p><p>&nbsp;</p><p>In studies&nbsp;1 and 2, patients had a mean weekly itch severity score of between 13.7 and 14.5 at baseline and a mean UAS7 score of 29.5 and 31.7 respectively. Patients in safety study&nbsp;3 had a mean weekly itch severity score of 13.8 and a mean UAS7 score of 31.2 at baseline. Across all three studies, patients reported receiving on average 4 to 6&nbsp;medications (including H1 antihistamines) for CSU symptoms prior to study enrollment. Patients received Xolair at 75&nbsp;mg, 150&nbsp;mg or 300&nbsp;mg or placebo by subcutaneous injection every 4&nbsp;weeks for 24 and 12&nbsp;weeks in studies&nbsp;1 and 2, respectively, and 300&nbsp;mg or placebo by subcutaneous injection every 4&nbsp;weeks</p><p>for 24&nbsp;weeks in study&nbsp;3. All studies had a 16‑week treatment-free follow-up period.</p><p>&nbsp;</p><p>The primary endpoint was the change from baseline to week&nbsp;12 in weekly itch severity score. Omalizumab at 300&nbsp;mg reduced the weekly itch severity score by 8.55 to 9.77 (p &lt;0.0001) compared to a reduction of 3.63 to 5.14 for placebo (see Table&nbsp;9). Statistically significant results were further observed in the responder rates for UAS7&le;6 (at week&nbsp;12) which were higher for the 300&nbsp;mg treatment groups, ranging from 52‑66% (p&lt;0.0001) compared to 11‑19% for the placebo groups, and complete response (UAS7=0) was achieved by 34‑44% (p&lt;0.0001) of patients treated with 300&nbsp;mg compared to 5‑9% of patients in the placebo groups. Patients in the 300&nbsp;mg treatment groups achieved the highest mean proportion of angioedema-free days from week&nbsp;4 to week&nbsp;12, (91.0‑96.1%; p&lt;0.001) compared to the placebo groups (88.1‑89.2%). Mean change from baseline to week&nbsp;12 in the overall DLQI for the 300&nbsp;mg treatment groups was greater (p&lt;0.001) than for placebo showing an improvement ranging from 9.7‑10.3&nbsp;points compared to 5.1‑6.1&nbsp;points for the corresponding placebo groups.</p><p>&nbsp;</p><p><strong>Table&nbsp;9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change from baseline to week&nbsp;12 in weekly itch severity score, studies&nbsp;1, 2 and 3 (mITT population*)</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:80%"><tbody><tr><td style="vertical-align:top"><table border="0" cellspacing="0" cellpadding="0" style="width:80%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>Placebo</strong></p></td><td style="vertical-align:bottom"><p><strong>Omalizumab<br />300&nbsp;mg</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Study&nbsp;1</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; N</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>81</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Mean (SD)</p></td><td style="vertical-align:top"><p>&minus;3.63 (5.22)</p></td><td style="vertical-align:top"><p>&minus;9.40 (5.73)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Difference in LS means vs. placebo<sup>1</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&minus;5.80</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 95% CI for difference</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&minus;7.49,&minus;4.10</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; P-value vs. placebo<sup>2</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Study&nbsp;2</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; N</p></td><td style="vertical-align:top"><p>79</p></td><td style="vertical-align:top"><p>79</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Mean (SD)</p></td><td style="vertical-align:top"><p>&minus;5.14 (5.58)</p></td><td style="vertical-align:top"><p>&minus;9.77 (5.95)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Difference in LS means vs. placebo<sup>1</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&minus;4.81</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 95% CI for difference</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&minus;6.49,&minus;3.13</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; P-value vs. placebo<sup>2</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Study&nbsp;3</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; N</p></td><td style="vertical-align:top"><p>83</p></td><td style="vertical-align:top"><p>252</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Mean (SD)</p></td><td style="vertical-align:top"><p>&minus;4.01 (5.87)</p></td><td style="vertical-align:top"><p>&minus;8.55 (6.01)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Difference in LS means vs. placebo<sup>1</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>‑4.52</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 95% CI for difference</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&minus;5.97, &minus;3.08</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; P-value vs. placebo<sup>2</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&lt;0.0001</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>*Modified intent-to-treat (mITT) population: included all patients who were randomised and received at least one dose of study medication.</p><p>BOCF (Baseline Observation Carried Forward) was used to impute missing data.</p><p><sup>1</sup> The LS mean was estimated using an ANCOVA model. The strata were baseline weekly itch severity score (&lt;13 vs. &ge;13) and baseline weight (&lt;80&nbsp;kg vs. &ge;80&nbsp;kg).</p><p><sup>2</sup> p-value is derived from ANCOVA t-test.</p><p>&nbsp;</p><p>Figure&nbsp;2 shows the mean weekly itch severity score over time in study&nbsp;1. The mean weekly itch severity scores significantly decreased with a maximum effect around week&nbsp;12 that was sustained over the 24‑week treatment period. The results were similar in study&nbsp;3.</p><p>&nbsp;</p><p>In all three studies the mean weekly itch severity score increased gradually during the 16‑week treatment-free follow-up period, consistent with symptom re-occurrence. Mean values at the end of the follow-up period were similar to the placebo group, but lower than respective mean</p><p>baseline values.</p><p>&nbsp;</p><p><img alt="" width="832" height="491" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>The magnitude of the efficacy outcomes observed at week&nbsp;24 of treatment was comparable to that observed at week&nbsp;12:</p><p>For 300&nbsp;mg, in studies&nbsp;1 and 3, the mean decrease from baseline in weekly itch severity score was 9.8 and 8.6, the proportion of patients with UAS7&le;6 was 61.7% and 55.6%, and the proportion of patients with complete response (UAS7=0) was 48.1% and 42.5%, respectively, (all p&lt;0.0001, when compared to placebo).</p><p>&nbsp;</p><p>Clinical trial data on adolescents (12 to 17&nbsp;years) included a total of 39&nbsp;patients, of whom 11 received the 300&nbsp;mg dose. Results for the 300&nbsp;mg are available for 9&nbsp;patients at week&nbsp;12 and 6&nbsp;patients at week&nbsp;24, and show a similar magnitude of response to omalizumab treatment compared to the adult population. Mean change from baseline in weekly itch severity score showed a reduction of 8.25 at week&nbsp;12 and of 8.95 at week&nbsp;24. The responder rates were: 33% at week&nbsp;12 and 67% at week&nbsp;24 for UAS7=0, and 56% at week&nbsp;12 and 67% at week&nbsp;24 for UAS7&le;6.</p><p>&nbsp;</p><p>In a 48‑week study, 206&nbsp;patients aged between 14 and 75&nbsp;years were enrolled into a 24‑week open‑label treatment period of omalizumab 300&nbsp;mg every 4&nbsp;weeks. Patients who responded to treatment in this open‑label period were then randomised to receive omalizumab 300&nbsp;mg (81&nbsp;patients) or placebo (53&nbsp;patients) every 4&nbsp;weeks for an additional 24&nbsp;weeks.</p><p>&nbsp;</p><p>Of the patients who remained on omalizumab treatment for 48&nbsp;weeks, 21% experienced clinical worsening (UAS7 score &sup3;12 for at least 2&nbsp;consecutive weeks post‑randomisation between weeks&nbsp;24 and 48), versus 60.4% of those treated with placebo at week&nbsp;48 (difference ˗39.4%, p&lt;0.0001, 95% CI: -54.5%, -22.5%).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of omalizumab have been studied in adult and adolescent patients with allergic asthma as well as in adult patients with CRSwNP, and adult and adolescent patients with CSU. The general pharmacokinetic characteristics of omalizumab are similar in these patient populations.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>After subcutaneous administration, omalizumab is absorbed with an average absolute bioavailability of 62%. Following a single subcutaneous dose in adult and adolescent patients with asthma or CSU, omalizumab was absorbed slowly, reaching peak serum concentrations after an average of 6‑8&nbsp;days. In patients with asthma, following multiple doses of omalizumab, areas under the serum concentration-time curve from Day&nbsp;0 to Day&nbsp;14 at steady state were up to 6-fold of those after the first dose.</p><p>&nbsp;</p><p>The pharmacokinetics of omalizumab are linear at doses greater than 0.5&nbsp;mg/kg. Following doses of 75&nbsp;mg, 150&nbsp;mg or 300&nbsp;mg every 4&nbsp;weeks in patients with CSU, trough serum concentrations of omalizumab increased proportionally with the dose level.</p><p>&nbsp;</p><p>Administration of Xolair manufactured as a lyophilised or liquid formulation resulted in similar serum concentration-time profiles of omalizumab.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p><em>In vitro</em>, omalizumab forms complexes of limited size with IgE. Precipitating complexes and complexes larger than one million Daltons in molecular weight are not observed <em>in vitro</em> or <em>in vivo</em>. Based on population pharmacokinetics, distribution of omalizumab was similar in patients with allergic asthma and patients with CSU. The apparent volume of distribution in patients with asthma following subcutaneous administration was 78&nbsp;&plusmn;&nbsp;32&nbsp;ml/kg.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Clearance of omalizumab involves IgG clearance processes as well as clearance via specific binding and complex formation with its target ligand, IgE. Liver elimination of IgG includes degradation in the reticuloendothelial system and endothelial cells. Intact IgG is also excreted in bile. In asthma patients the omalizumab serum elimination half-life averaged 26&nbsp;days, with apparent clearance averaging 2.4&nbsp;&plusmn;&nbsp;1.1&nbsp;ml/kg/day. Doubling of body weight approximately doubled apparent clearance. In CSU patients, based on population pharmacokinetic simulations, omalizumab serum elimination half-life at steady state averaged 24&nbsp;days and apparent clearance at steady state for a patient of 80&nbsp;kg weight was 3.0&nbsp;ml/kg/day.</p><p>&nbsp;</p><p><u>Characteristics in patient populations</u></p><p>&nbsp;</p><p><em><u>Age, Race/ethnicity, Gender, Body Mass Index</u></em></p><p><em>Patients with allergic asthma and </em><em>chronic rhinosinusitis with nasal polyps (CRSwNP)</em></p><p>The population pharmacokinetics of omalizumab were analysed to evaluate the effects of demographic characteristics. Analyses of these limited data suggest that no dose adjustments are necessary for age (6‑76&nbsp;years for patients with allergic asthma; 18 to 75 for patients with CRSwNP), race/ethnicity, gender or body mass index (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em>Patients with CSU</em></p><p>The effects of demographic characteristics and other factors on omalizumab exposure were evaluated based on population pharmacokinetics. In addition, covariate effects were evaluated by analysing the relationship between omalizumab concentrations and clinical responses. These analyses suggest that no dose adjustments are necessary in patients with CSU for age (12‑75&nbsp;years), race/ethnicity, gender, body weight, body mass index, baseline IgE, anti-FceRI autoantibodies or concomitant use of H2 antihistamines or LTRAs.</p><p>&nbsp;</p><p><em><u>Renal and hepatic impairment</u></em></p><p>There are no pharmacokinetic or pharmacodynamic data in allergic asthma or CSU patients with renal or hepatic impairment (see sections&nbsp;4.2 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety of omalizumab has been studied in the cynomolgus monkey, since omalizumab binds to cynomolgus and human IgE with similar affinity. Antibodies to omalizumab were detected in some monkeys following repeated subcutaneous or intravenous administration. However, no apparent toxicity, such as immune complex-mediated disease or complement-dependent cytotoxicity, was seen. There was no evidence of an anaphylactic response due to mast-cell degranulation in cynomolgus monkeys.</p><p>&nbsp;</p><p>Chronic administration of omalizumab at dose levels of up to 250&nbsp;mg/kg (at least 14&nbsp;times the highest recommended clinical dose in mg/kg according to the recommended dosing table) was well tolerated in non-human primates (both adult and juvenile animals), with the exception of a dose-related and age-dependent decrease in blood platelets, with a greater sensitivity in juvenile animals. The serum concentration required to attain a 50% drop in platelets from baseline in adult cynomolgus monkeys was roughly 4- to 20-fold higher than anticipated maximum clinical serum concentrations. In addition, acute haemorrhage and inflammation were observed at injection sites in cynomolgus monkeys.</p><p>&nbsp;</p><p>Formal carcinogenicity studies have not been conducted with omalizumab.</p><p>&nbsp;</p><p>In reproduction studies in cynomolgus monkeys, subcutaneous doses up to 75&nbsp;mg/kg per week (at least 8&nbsp;times the highest recommended clinical dose in mg/kg over a 4‑week period) did not elicit maternal toxicity, embryotoxicity or teratogenicity when administered throughout organogenesis and did not elicit adverse effects on foetal or neonatal growth when administered throughout late gestation, delivery and nursing.</p><p>&nbsp;</p><p>Omalizumab is excreted in breast milk in cynomolgus monkeys. Milk levels of omalizumab were 0.15% of the maternal serum concentration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>L-arginine hydrochloride</p><p>L-histidine hydrochloride</p><p>L-histidine</p><p>Polysorbate 20</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 months.

The product may be kept for a total of 48 hours at 25°C. If necessary, the product may be returned to the refrigerator for later use.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C ‑ 8&deg;C).</p><p>Do not freeze.</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Xolair 150 mg solution for injection in pre-filled syringe (26-gauge staked needle, purple syringe guard)</u></p><p>Xolair 150 mg solution for injection in pre-filled syringe is supplied as 1 ml solution in a pre-filled syringe barrel (type I glass) with 26-gauge staked needle (stainless steel), (type I) plunger stopper and needle cap.</p><p>&nbsp;</p><p>Pack sizes: packs containing 1 pre-filled syringe, and multipacks containing 4 (4 x 1); 6 (6 x 1) or 10 (10 x 1) pre-filled syringes.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pre-filled syringe</u></p><p>Xolair 150&nbsp;mg solution for injection is supplied in a single-use pre-filled syringe for individual use. The syringe should be taken out of the refrigerator 20&nbsp;minutes before injecting to allow it to reach room temperature.</p><p>&nbsp;</p><p><u>Disposal instructions</u></p><p>Dispose of the used syringe immediately in a sharps container.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>